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ABBREVIATIONS (in alphabetical order)
 
1,25(OH)2D 
 
1,25-Dihydroxyvitamin D 
25(OH)D 25-Hydroxyvitamin D 
7-DHC 7-Dehydrocholesterol  
BB-UVB Broadband Ultraviolet B  
BCa Breast Cancer 
BMD Bone Mineral Density  
BMI Body Mass Index 
CD Crohn’s disease 
CIE The International Commission on Illumination 
CLIA Chemiluminescent Immunoassay  
CMM Cuteneous Malignant Melanoma  
CRC Colorectal Cancer 
CYP24A1 24-hydroxylase 
CYP27B1 1-hydroxylase  
CYP2R1 25-hydroxylase
DBP Vitamin D binding protein  
E-BSA Exposed Body Surface Area 
ECa Endometrial Cancer  
FGF23 Fibroblast Growth Factor-23 
GWAS Genome-Wide Association Study
HPLC High-Performance Liquid Chromatography
IU International Units 
LC-MS Liquid Chromatography-Mass Spectrometry  
MED Minimal Erythema Dose 
MS Multiple Sclerosis  
mVDR Membrane vitamin D receptor 
NB-UVB Narrowband Ultraviolet B 
NIST National Institute of Standards and Technology
nVDR Nuclear vitamin D receptor 
OR Odds Ratio 
PCa Prostate Cancer 
PTH Parathyroid hormone 
RA Rheumatoid Arthritis  
RCT Randomized Clinical Trial  
RDD  Recommended daily dose for vitamin D intake  
RIA Radio-Immunoassay
RR Relative risk  
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RXR Retinoic X Receptors
Sun1 Sun bed – Life Sun S 100W 
Sun2 Sun bed – Solarium Super Plus 100 W 
Sun3 Sun bed – Golden Sun RS 100 W + Beauty Sun 25 W 
SDD Standard vitamin D dose 
SED Standard erythema dose 
sHPT Secondary Hyperparathyroidism 
SLE Systemic Lupus Erythematosus   
SPF Sun Protection Factor  
SZA Solar Zenith Angle  
T1D Type 1 Diabetes  
TUL Tolerable Upper Limit  
UVA Ultraviolet A (320-400nm) 
UVB Ultraviolet B (280-320 nm) 
UVD3 Previtamin D3 weighted UV 
UVEry Erythema weighted UV 
UVI Ultraviolet Index 
UVR Ultraviolet Radiation  
VDDS Vitamin D Deficiency Syndrome  
VDRE Vitamin D-Responsive Element
DEQAS Vitamin D External Quality Assessment Scheme 
RELEVANT UNITS AND CONVERSIONS 
1,25(OH)2D:  Concentration [pmol/L] = 2.4 x Concentration [pg/ml]
25(OH)D: Concentration [nmol/L] = 2.5 x Concentration [ng/ml]
SED: Dose [J/m2]  = 0.1 x Dose [mJ/cm2]
Vitamin D intake: Dose [IU]  = 40 x Dose [µg]
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FACTS ABOUT VITAMIN D  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VITAMIN D: VITAMIN D3 (cholecalciferol) and VITAMIN D2 (ergocalciferol) 
 
Vitamin D, the “sunshine vitamin“, is a fat-soluble steroid pro-hormone. Vitamin D 
is a biologically inert compound, and has to undergo a number of conversions in 
order to become an active hormone. The main source of vitamin D3 for humans is 
sun exposure. Another important source for vitamin D is food. Vitamin D3 is present 
in few animal foods, mainly fat fish, while vitamin D2 is found in some wild 
mushrooms. Both vitamin D forms are available in supplements. The high dose 
supplementation available in Norway is a vitamin D2 form. 
25-HYDROXYVITAMIN D (CALCIDIOL or 25(OH)D) 
 
Vitamin D, produced in the skin or obtained from food and supplements, undergoes 
its first hydroxylation in the liver and becomes 25(OH)D. Serum 25(OH)D is the 
major form of vitamin D and the most reliable determinant of vitamin D status. 
Serum 25(OH)D concentrations reflect well the cutaneous vitamin D synthesis and 
ingested vitamin D. According to the classification proposed by M.F. Holick, one of 
the world leaders in vitamin D research, vitamin D deficiency should be defined as 
serum 25(OH)D levels < 50 nmol/L, vitmin D insufficiency as 50-74 nmol/L, and 
vitamin D sufficiency as values  75 nmol/L.
1,25-DIHYDROXYVITAMIN D (CALCITRIOL or 1,25(OH)2D) 
 
In the kidneys 25(OH)D undergoes the second hydroxylation to 1,25(OH)2D. Serum 
1,25(OH)2D is an active steroid hormone that regulates calcium homeostasis and 
bone mineralization. Vitamin D status can not be determined by 1,25(OH)2D 
measurements, since its serum concentrations are tightly regulated and may remain 
normal even in the setting of vitamin D deficiency. The 1,25(OH)2D signaling 
pathway is mediated through the vitamin D receptor (VDR). Almost 40 tissues in the 
human body express VDR. Thus, it has been recently proposed that 1,25(OH)2D 
may be involved in regulation of many physiological functions.
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1. ABSTRACT  
Sun is the main vitamin D source for humans. Sun exposure during the summer may provide 
large amounts of vitamin D3, which is stored in the fat tissue and released during the winter. 
Serum 25(OH)D levels > 80 nmol/L at the end of the summer are considered necessary in 
order to avoid vitamin D deficiency during the winter. However, it is not clear how much sun 
exposure is needed to achieve this concentration. In this study we simulated a Norwegian 
summer by using commercially available tanning equipment. We found that moderate 
exposures given during 5-7 weeks may raise serum 25(OH)D concentrations from typical 
winter values to typical summer values. A UV dose equal to a whole body sun exposure of 5 -
10 MED at sunny summer midday increased serum 25(OH)D by 15-23 nmol/L. The increase 
was dependent on the initial vitamin D status: persons with the lowest baseline 25(OH)D 
concentrations got the largest increase. However, for persons with vitamin D deficiency 
(25(OH)D < 50 nmol/L) the mentioned UV exposure was not large enough to reach the 
threshold of vitamin D sufficiency (25(OH)D  75 nmol/L). Moreover, a daily whole body sun 
exposure of ~0.2 MED seems to be almost equal to an oral vitamin D intake of 2,000 IU.  
 
Body composition and BMI are important predictors of vitamin D status. Our earlier 
investigations suggested that serum 25(OH)D levels decrease proportionally with increasing 
BMI. The key mechanism behind is possibly increased sequestration of fat-soluble vitamin D 
in a large volume of fat tissue. However, other factors, such as low sun exposure and 
inadequate vitamin D intake, may also contribute to the low vitamin D status in overweight 
and obese persons. In this study we have investigated the impact of excess body weight on 
serum 1,25(OH)2D concentrations. According to our results high BMI and adiposity in adults 
were associated with decreased serum 1,25(OH)2D. Serum 25(OH)D was the strongest 
predictor of 1,25(OH)2D values. A decrease in 25(OH)D by 1 nmol/L was associated with a 
decrease in 1,25(OH)2D concentrations by 0.4 pmol/L (P<0.001). There was no correlation 
between serum concentrations of 25(OH)D and 1,25(OH)2D in obese children and adolescents, 
although the prevalence of vitamin D deficiency and insufficiency in adolescents was high (58 
%).  
 
Low vitamin D status as a consequence of low sun exposure and/or high BMI may play a role 
in cancer development and prognosis. Our calculations suggest that a low vitamin D status may 
explain at least 20% of the cancer risk attributable to high BMI. It also seems that the 
contribution of low 25(OH)D to the increased cancer risk with increasing BMI may be 
different for different cancer types being highest for colorectal and breast cancers.  
 
A panel of 25 world leaders in vitamin D research recommended that the serum 25(OH)D 
concentrations should be at least  75 nmol/L (30 ng/ml) in order to provide optimal health 
outcomes. These values may be achieved by moderate UV exposure or by high vitamin D 
intake. The dose of vitamin D supplementation and UV exposure should be adjusted according 
to BMI.  
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2. AIMS OF THE STUDY  
The objective of this study was to investigate the complex association between vitamin D 
predictors (UV exposure, BMI, vitamin D intake), serum 25(OH)D concentrations, and  cancer 
risk.  
  
In order to investigate the effect of UV exposure on serum 25(OH)D concentrations a 
Norwegian summer was simulated by using commercially available tanning equipment during 
the winter. Thus, our aims were: 
 
 to investigate the effect of moderate UV exposure on vitamin D status 
 to investigate the impact of initial vitamin D status on serum 25(OH)D increase 
 to investigate the role of body weight and vitamin D intake on serum 25(OH)D increase 
 to compare the efficiency of high dose vitamin D supplementation and moderate UV 
exposure to increase serum 25(OH) concentrations 
 
To determine the association between excess body weight, vitamin D status, and serum 
1,25(OH)2D concentrations we analyzed a data base containing relevant data for almost 1,900 
adults and children with overweight and obesity. We aimed to:   
 
 investigate the prevalence of vitamin D deficiency and insufficiency 
 estimate the associations between body composition, BMI, age, gender, and serum 
concentrations of 25(OH)D and 1,25(OH)2D 
 investigate the association between serum 1,25(OH)2D and 25(OH)D 
 study the seasonal variation of both serum 25(OH)D and 1,25(OH)2D 
 
Furthermore, we wanted to investigate if low vitamin D status related to high BMI plays any 
role in cancer development. We aimed to:   
 
 estimate the possible contribution of  vitamin D to cancer risk attributable to high BMI 
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3. VITAMIN D SYNTHESIS AND METHABOLISM  
Vitamin D, also known as the “sunshine vitamin“, is a fat-soluble steroid pro-hormone. It is 
available in two distinct forms: cholecalciferol (Vitamin D3) and ergocalciferol (vitamin D2) 
(Figure 1) (1).  
The main source of vitamin D3 for humans is sun (2). About 90-95% of total vitamin D 
is produced in the skin (3). Another important source for vitamin D is food (4). Vitamin D3 is 
present in few animal foods, mainly fat fish, while vitamin D2 is found in some wild 
mushrooms (4). Both vitamin D forms are available in supplements. Although in a number of 
studies vitamin D3 has proven to be the most potent form for humans, both vitamin D forms 
are still regarded as equivalent and interchangeable (5).  
 
 
Figure 1. Two distinct forms of vitamin D 
 
3.1. Cutaneous vitamin D3 synthesis 
Exposure of uncovered skin to ultraviolet B radiation (UVB) (280-320 nm) generates 
previtamin D3 from 7-dehydrocholesterol in the plasma membranes of the cells in upper skin 
layers, mainly in the stratum basale and the stratum spinosum (3;6). Previtamin D3 undergoes a 
rapid thermal isomerization to vitamin D3. Once formed, vitamin D3 is ejected out of the 
plasma membrane into extracellular space, where it enters the bloodstream and binds to 
vitamin D binding protein (DBP) (3).  
 The concentrations of previtamin D3 in the skin reaches its maximum within hours, 
however it may take 24-48 hours to few days until serum vitamin D levels increase (7). Under 
prolonged UVB exposure both previtamin D3 and vitamin D3 can be converted to several 
biologically inactive photoproducts, mainly lumisterol and tachysterol (8). These compounds 
may also be converted back when the concentrations of previtamin D3 decreases. Thus, 
excessive sun exposure does not result in vitamin D intoxication (8).  
 
 CH3
OH
CH2
OH
CH2
CH3
CH3
H3C
CH3
H3C
Vitamin D3
Cholecalciferol
CH3
Vitamin D2
Ergocalciferol
H3C
H3C
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3.2. Vitamin D metabolism  
Vitamin D is a biologically inert compound, and has to undergo a number of conversions in 
order to become an active hormone (3;6). In the blood stream vitamin D and its metabolites are 
bound to DBP that plays an important role in maintaining vitamin D status (Figure 2) (9).  
 
3.2.1. From a vitamin to an active hormone. DBP transports vitamin D to the liver where it 
undergoes the first hydroxylation to 25-hydroxivitamin D (25(OH)D) catalysed by one or more 
cytochrome P450 vitamin D 25-hydroxylases (CYP2R1, CYP27A1) (10). Other cytochrome 
P450 enzymes may also be involved in vitamin D 25-hydroxylation (11;12). Genetic variations 
of CYP2R1 may influence serum 25(OH)D concentrations (13).  In the blood steam 25(OH)D 
binds to DBP to be transported to the kidneys and other tissues. In the kidneys 25(OH)D 
undergoes a second hydroxylation to 1,25-dihydroxyvitamin D (1,25(OH)2D) by 1-
hydroxylase (CYP27B1) (10). The renal expression of CYP27B1 is up-regulated by 
parathyroid hormone (PTH), low serum calcium, and high phosphates concentrations, and 
down-regulated by fibroblast growth factor 23 (FGF 23) and high 1,25(OH)2D (12;14). At the 
same time, low PTH, high calcium, and low phosphates concentrations stimulate expression of 
24-hydroxylase (CYP24A1), an enzyme that catabolizes both 25(OH)D and 1,25(OH)2D to 
calcitroic acid (11). 
 
Vitamin D2 and D3 from 
food and supplements 
Skin
D3/D2 DBP
25(OH)DDBP
25(OH)DDBP
Serum 1,25(OH)2DDBP
Intracellular 1,25(OH)2D
Normal cells
Kidneys 
Liver
Diseased cells
Intracellular 
1,25(OH)2D
• Calcium homeostasis
• Bone health 
• Cardiovascular health 
• Methabolic functions
• Immune function
• Cell growth
• Differentiation 
• Angiogenesis 
• Apoptosis
• Local regulation of cell metabolism
290-320 nm
D3
UVB
 
Figure 2. Vitamin D sources and metabolism.  
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Although, CYP27B1 is found predominantly in kidneys, it is also expressed by many 
other cell types, such as macrohages, T-lymphocytes, dendritic cells, keratinocytes, bone, 
placenta and prostate cells (15;16).  Several types of cancer cells (intestine, prostate, lung, skin 
etc.) may also convert 25(OH)D to 1,25(OH)2D (10;16). It has recently been revealed that a 
few cell types (keratinocytes, macrophages, prostate epithelial cells, osteoblasts) may 
metabolize vitamin D to 1,25(OH)2D (10). 
 
3.2.2. The role of DBP in vitamin D metabolism. In the blood circulation vitamin D 
metabolites are bound to DBP and to other proteins (9). The main functions of DBP are 
solubilization and transport of vitamin D metabolites to target tissues. Binding to DBP 
decreases the bioavailability of vitamin D active metabolites, and, possibly, prevents vitamin D 
intoxication (17). It may also preserve vitamin D metabolites from fast catabolism, thus, 
increasing their half-life time. In this case, DBP acts as a reservoir for vitamin D circulating 
forms. Serum DBP concentrations are 100-fold higher than those of 25(OH)D, and only 5% of 
DBP binding sites are occupied by vitamin D methabolites (17). The binding affinity of DBP is 
different for each vitamin D metabolite, and is highest for 25(OH)D. Approximately 88% of 
serum 25(OH)D, 85% of serum 1,25(OH)2D, but only 60% of vitamin D are bound to DBP 
(17;18). DBP is a highly polymorphic protein (19). Genetic variants of DBP have been 
associated with large differences in binding affinity to vitamin D ligands, and may explain 
much of the interpersonal variation in the levels circulating 25(OH)D and 1,25(OH)2D (20). 
DBP polymorphism also predicts response of serum 25(OH)D to vitamin D supplementation 
and sun exposure (13;19;21).   
 
3.3. Mechanisms of vitamin D action  
1,25(OH)2D is transported from the kidneys by DBP to organs and tissues where it acts in both 
genomic or non-genomic manner (10;22) Vitamin D signaling is mediated through vitamin D 
receptor that may be located in the cell nucleus (nVDR) or the cell membrane (mVDR) (22). 
Almost 40 tissues express one or both types of VDR (22), and about 3% of the human genome 
may be regulated by 1,25(OH)2D (23). 
 
3.3.1. Genomic vitamin D response is mediated through nVDR and takes hours or even days 
(10;22). VDR is functioning as a heterodimer and commonly recruits retinoid X receptor 
(RXR). VDR-RXR heterodimers build complexes with co-regulatory proteins that further 
interact with specific genomic sequences, vitamin D response elements (VDRE), in the 
promoter region of target genes (10;22).  
The study by Ramagopalan et al. on lymphoblastoid cell lines provides a high-
resolution map of VDR binding throughout the human genome, and indicates 2776 binding 
sites and 229 genes that can be up- or down-regulated in response to 1,25(OH)2D stimulation 
(24).  The VDR binding activity was high around the genes that, according to recent genome-
wide association studies (GWAS) were associated with multiple sclerosis (MS), diabetes type 
1 (T1D), Crohn’s disease (CD), systemic lupus erythematosus (SLE), rheumatoid arthritis 
(RA), chronic lymphocytic leukemia, colorectal cancer, hair color, tanning, and height (Figure 
3) (24;25). Interestingly, VDR binds more actively to the regions responsible for positive 
selection (hair color, skin sensitivity). This suggests an important role of vitamin D in human 
evolution (24). Although these data strongly support pleiotropic vitamin D activities, further 
research is needed to identify the particular molecular mechanisms behind vitamin D action.   
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VDR activation regulates the expression of at least 11 genes essential for calcium 
homeostasis and bone health including SPP1 (osteopontin), TRPV6 (selective calcium 
channel), LRP5 (low density lipoprotein receptor-related protein 5), BGP, RANKL (receptor 
activator for nuclear factor  B ligand), OPG (osteoprotegerin), CYP24A1, PTH, FGF23, 
PHEX (phosphate-regulating gene) and klotho protein (26). 
 
3.3.2. Non-genomic vitamin D responses are probably mediated through mVDR (27). The 
non-genomic mechanism of action include activation of  protein kinase C (PKC), mitogen-
activated protein kinase (MAPK), phosholipase A2 (PLA2), phospholipase C (PLC), G-protein 
and opening of ion channels (22). The time required for non-genomic effects may vary from a 
few seconds to 10-60 minutes (22).  
 
The effects of vitamin D are commonly subdivided as classical and non-classical 
(8;28). The main classical role of 1,25(OH)2D is to maintain mineral homeostasis and bone 
health by increasing the absorption of calcium and phosphates in intestine and reabsorption in 
kidneys, regulation of serum PTH and  FGF23 levels, and control of bone growth, 
mineralization and remodeling (29;30).  
Among non-classical vitamin D actions may be listed inhibition of cell proliferation 
and induction of differentiation, regulation of innate and anti-bacterial immune responses and 
control over hormone secretion (8). These mechanisms explain the essential role of vitamin D 
in muscle function, cardiovascular homeostasis, nervous function, immune, endocrine, and 
circulatory systems (31)  
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2,2
2,8
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7,2
8,3
0 1 2 3 4 5 6 7 8 9
Height 
Multiple sclerosis 
Rheumatoid arthritis 
Diabetes type 1 
Crohn’s disease 
Colorectal cancer
Systemic lupus erythematosus
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Chronic lymphocytic leukemia
 
                         VDR binding activity  
Figure 3. VDR binding activity around the genes related to common diseases identified by 
recent genome-wide association studies (GWAS) (24). 
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4. VITAMIN D SOURCES 
Vitamin D may be obtained from UVB exposure (sun, tanning units, narrowband, and 
broadband UVB lamps) and dietary intake (unfortified and fortified foods and supplements).   
 
4.1. Sun and artificial UVB sources  
Sun is definitely the cheapest, the most available and the most natural vitamin D source among 
all possible sources of UVB (32).  However, it is probably not the most efficient one. 
Broadband and narrowband UVB cabinets for psoriasis treatment, as well as some tanning 
units commercially available in Europe, seem to be more efficient sources for vitamin D, if one 
takes into account shorter irradiation times and larger body area that can be exposed at the 
same time.   
The main differences between sun and artificial UVB sources are intensity and 
proportional content of UVB, ultraviolet A (UVA) (320-400nm), and visible light (Figure 4). 
These basic differences may have impacts on health effects of UV radiation, including vitamin 
D synthesis.  
 
 
Figure 4. Sources of UVB radiation.  
 
4.1.1. Erythema- and vitamin D- weighted UV. Even short exposures to the sun may 
produce a large amount of vitamin D3 (33). UV exposure of the whole body to one minimal 
erythema dose (MED) seems to increase serum vitamin D3 levels equivalent with an oral dose 
of 10,000-20,000 IU (3).  
 
4.1.1.1. Minimal erythema dose (MED) is defined as the minimal UV dose required to 
produce perceptible erythema (a slight pinkness) to the skin as determined 24 hours after 
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exposure to UV source (34). MED can be expressed in minutes or in UV dose (J/m2), adjusted 
to the International Commission on Illumination (CIE) recommended action spectra for 
erythema (35). The MED is an individual and often subjective indicator of skin sensitivity to 
UV radiation. It varies with skin pigmentation, skin type, UV intensity and other factors (36). 
Therefore, standardized MED for each skin type were developed (Table 1).  
 
4.1.1.2. Standard erythema dose (SED). Due to very high interindividual variations of MED it 
is not always convenient to describe the UV doses in MED, especially in large populations, at 
different latitudes and with different UV sources. Thus, SED is more often used to describe 
occupational and controlled UV exposure as well as effects of different UV doses on human 
health, including cutaneous vitamin D3 synthesis (37). The SED equals to 100 J/m2 weighted 
by CIE erythema action spectrum and the emission spectrum of the UV source (37). Thus, the 
SED is a more accurate measure of physical UV exposure than MED. 
 
Table 1. MED and SED in different skin types (34;38) 
 
Skin 
type 
 
Reaction to sun 
 
MED 
(J/m2) 
 
MED 
(min)* 
 
SED 
 
I 
 
Always burns; never tans 
 
200 
 
22 
 
2 
II Burns easily; tans minimally  250 28 2.5 
III Burns moderately; tans gradually 300 33 3 
IV Rarely burns; tans easily  450 50 4.5 
V Very rarely burns; tans substantially 600 67 6 
VI Never burns; deeply pigmented  1000 111 10 
 
* Oslo, 12:00 a.m. 22 June 2010, 1 SED = 11 minutes 
4.1.1.3. UV index (UVI) is another important measure of UVR (32). UVI is calculated by the 
formula: UVI = 40 x UVEry, where UVEry is CIE erythema weighted UV (W/m2) (39). UVI are 
usually presented as a scale from 1 to 15 that indicates the risk level of possible skin damage 
due to UV exposure.  Based on UV index, the number of SED achieved per hour can be 
calculated (SED h-1) (Figure 5) (32).   
 
4.1.1.4. Standard vitamin D dose (SDD). To estimate the efficiency of UV source to induce 
vitamin D3 synthesis it has been also proposed to use vitamin D weighted UV dose (UVD3) and 
SDD (33). UVD3 dose may be calculated as the area under the curve obtained by multiplication 
of CIE vitamin D action spectrum and the emission spectrum of the UV source (Figure 6) 
(40;41). The ratio between UVD3 and UVEry indicates the benefit/risk balance, and shows the 
efficiency of light source to induce vitamin D synthesis during certain erythema dose (42).  
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Figure 5. Range of UVI and corresponding exposure for erythema (SED h-1) and vitamin D     
synthesis for skin type II (32) 
 
The SDD is defined as the UV dose necessary for a serum vitamin D3 increase equal to 
an oral vitamin D dose of 1000 IU (33). According to Holick, SDD may be achieved by a UV 
exposure of ¼ skin area (hands, face and arms) to ¼ of personal MED (33). The SDD is in a 
way a similar measure as MED for erythema, but only for vitamin D synthesis. Thus, it feels 
right to suggest a measure similar to SED, which will reflect a fixed dose of CIE vitamin D 
weighted UV. According to the results of our recent study, a vitamin D weighted UV dose of 
about 100 J/m2 may possibly be as effective to improve vitamin D status as an oral vitamin D3 
dose of 2000 IU (43). Thus, a dose of 100 J/m2 of vitamin D weighted UV may be a good 
candidate dose for proposed measure. For Oslo sun this dose will be equal to ~0.6 SED of 
whole body exposure.  
  
 
Figure 6. Action spectra of erythema, previtamin D3, and sun in Gran Canaria (left panel). 
Efficiency spectra for vitamin D synthesis and erythema production (right panel). 
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4.1.2. Efficiency of vitamin D synthesis. The effectiveness of UV sources to induce vitamin 
D3 synthesis depends on UVB fluence rates, ratio between vitamin D weighed (UVD3) and 
erythema weighed UV (UVEry) (UVD3/ UVEry) and skin pigmentation (1;38;44-47).  
Solar UVB fluence rates, as well as UVD3/ UVEry, vary with latitude, season, weather 
conditions and day time (1;48;49). Thus, an optimal benefit to risk condition for vitamin D 
synthesis from solar UV exposure occurs under high solar altitude, low zenith angle, midday 
midsummer sunlight (42). 
Artificial sources of UV radiation include various lamps used both in medicine 
(psoriasis broadband and narrowband UVB lamps) and industry (sun bed lamps). According to 
state regulations, only type 3 sun beds are commercially available in Norway (50). The 
regulations limit the CIE erythema weighted UV to 0.3 W/m2 (0.15 W/m2 of  UVB and 0.15 
W/m2 of  UVA) (50). The intensity of broadband and narrow band UVB lamps used to treat 
psoriasis is 3-15-fold higher than that (51). The efficiency of artificial UV sources to induce 
vitamin D synthesis may be estimated based on UVD3/ UVEry that varies between 0.5 and 2 
depending on lamp type (42). The tanning units used in our studies had UVD3/ UVEry = 1.3 
(43;52). The UV doses for sun at different latitudes and tanning units used in the study are 
compared in Table 2. 
 
 
Table 2. UV doses of different UVB sources for the skin type II person (33;38;51).  
 
UV source 
 
MED 
(min) 
 
SED 
(min) 
 
UVD3 per 
SED (J/m2) 
 
UVD3/ 
UVEry 
 
SDD  
(min) 
 
Oslo Sun* 
 
28 
 
11 
 
170 
 
1.70 
 
7 
Gran Canaria Sun*  15 6 187 1.87 4 
Equator Sun*  11 4.3 188 1.88 3 
Tanning device Sun21 23 9 125 1.25 6 
Tanning devise Sun32 15 6 134 1.34 4 
 
* 11 a.m.-13 p.m. June 2010  
1 Solarium Super Plus 100 W 
2 Golden Sun RS 100W combined with Beauty Sun S 25 W  
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4.2. Food and supplements  
2.1. Food sources. There are only few foods that naturally contain vitamin D. Fatty fish 
(mackerel, salmon, herring) and cod liver oil are the major sources of vitamin D3 in Norway 
(Table 3) (53). Small amounts of vitamin D3 are also present in beef liver, eggs and meat (4). 
Some dairy products in Norway including butter, margarine, and milk are fortified with 
vitamin D3 (53). Vitamin D2 is found in wild mushrooms and plants (4). 
 
Table 3. Vitamin D content in unfortified and fortified foods  
 
Food  
 
μg 
 
IU 
 
%RDD* 
 
%TUL** 
 
Fish meal, 150g portion 
    
Fish liver (cod)  72.4 2900 725 145 
Mackerel (salmon, traut, herring) 17.5 700 175 35 
Cod roe 5.3 212 53 11 
Cod, saithe, haddock 3.0 120 30 6 
Fish soup, gratin 2.4 96 24 4.8 
Fish fingers, breaded 2.0 80 20 4 
Catfish 0.7 28 7 1.4 
Sandwich spread, 25 g      
Roe paste 6.0 240 60 12 
Sardines, herring, sprat 3.0 120 30 6 
Smoked salmon 1.4 56 14 2.8 
Mackerel 1.3 50 13 2.5 
Butter, margarine, 10 g 0.8 32 8 1.6 
Milk  (extra light), 1.5 dl  0.6 24 6 1.2 
Bakery products, cakes, 1 pc  0.4 16 4 0.8 
Egg, 1 pc  0.36 14 4 0.7 
 
*Recommended Daily Dose (RDD) in Norway is 400 IU 
** Tolerable Upper Limit (TUL) for daily vitamin D intake is 2,000 IU  
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4.2.2. In supplements vitamin D is available in both forms: vitamin D3 and vitamin D2. 
Although, there are mainly vitamin D3 supplements that are used in Norway (Table 4) (53). 
Cod liver oil (Tran) is traditionally one of the most popular vitamin D supplements in Norway 
with 60% of adult population using it (54).  
 
Table 4. Vitamin D content in supplements 
 
Supplements  
 
μg 
 
IU 
 
%RDD* 
 
%TUL** 
 
Vitamin D3 
    
Cod liver oil (Tran1), 5ml 10 400 100 20 
Cod liver oil (Tran capsules), 1 cp 5 200 50 10 
Nycoplus D-vitamin (tablets) 1 tab 10 400 100 20 
Nycoplus D-vitamin (drops), 5 dr 10 400 100 20 
Waifa- Calcium 500 mg + D-vitamin, 1 tab  10 400 100 20 
Calcigran forte Calcium 500 mg + D, 1 tab 10 400 100 20 
Sanasol, 5 ml 5 200 50 10 
Spektro multi (tablets), 1 tab 2.5 100 25 5 
Vitamin D2     
AFI-D 2 forte2 (capsules), 1 cp 750 30000 10702 2142 
 
*Recommended Daily Dose (RDD) in Norway is 400 IU 
** Tolerable Upper Limit (TUL) for daily vitamin D intake is 2,000 IU  
1Tran produced by different companies in Norway contains the same amount of vitamin D  
21 capsule per week is usually prescribed  
 
4.2.3. The daily recommended vitamin D intake (RDD) in Norway is 7.5 μg (300 IU) for 
adults, and 10 μg (400 IU) for children (6-23 months) and persons > 60 years (54). These 
recommendations are similar to those in other European countries (55). Vitamin D 
supplementation is usually recommended during the winter months when vitamin D3 can not 
be produced in the skin (56). 
The upper tolerable limit for vitamin D intake (UTL) (maximum daily intake unlikely 
to cause any health risks) is set to 2,000 IU (50 μg) for adults and at 1,000 IU (25 μg) for 
children (55;57).  However, it has been shown that vitamin D daily intake of doses <10,000 IU 
does not result in any sign of toxicity (9).  
Based on a report from National Nutrition Council (56), the intake of vitamin D with 
food in Norway is in the range of 3 to 6 μg/d, slightly lower in women (4.0 μg) than in men 
(5.8 μg). The total vitamin D intake (including supplements) is of the order of 4 to 14 μg/d 
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(56). The contribution of vitamin D supplements, unfortified and fortified foods to mean daily 
vitamin D intake in Norway seems to be the following: 45%, 30% and 25%, respectively (53). 
There is a large variation of daily vitamin D intake between different age groups, with the 
lowest intake among teenagers (58).  Significantly higher vitamin D intake was observed in 
northern Norway compared to southern of Norway (56;58;59).  That is probably due to high 
consumption of cod liver oil and fish including mølje (a traditional north Norwegian fish meal 
consisting of cod liver) (59). One mølje meal may provide the equivalent of 7-18 RDD (59).  
Although, Norway has few foods fortified with vitamin D3, it has one of the highest 
daily vitamin D intakes in Europe (60). Traditions of fish eating and high cod liver oil 
consumption might have contributed to that. 
 
5. VITAMIN D STATUS 
Vitamin D, produced in the skin or obtained from food and supplements, is a biologically inert 
compound, and is, therefore, not routinely measured in routine clinical practice (61). Although 
1,25(OH)2D is the most active vitamin D metabolite, serum 25(OH)D is the most abundant 
form of vitamin D and the most reliable determinant of vitamin D status (3;9;62). Serum 
25(OH)D concentrations reflects the cutaneous vitamin D synthesis and ingested vitamin D 
well (3;10).  Serum 1,25(OH)2D concentrations are about 0.01% of 25(OH)D values, and are 
in most cases strictly regulated by PTH, calcium and phosphate (3;61). Therefore, serum 
1,25(OH)2D is usually not considered for assessment of the vitamin D status. However, it may 
be a useful estimation in patients with kidney diseases and very low serum 25(OH)D (62).  
 
5.1. Measurements of vitamin D status   
There are many commercially available assays for vitamin D measurements. However, their 
comparability is uncertain (63). High-pressure liquid chromatography (HPLC) was considered 
as a “gold standard” for vitamin D status assessment, however, now it is not often used 
routinely (64;65). Radioimmunoassay (RIA) for 25(OH)D measurements was developed in 
1985, and became one of the most common methods for routine 25(OH)D evaluation 
(64;66;67). Other common methods are liquid chromatography-tandem mass spectrometry 
(LCMS), chemiluminescent immunoassays (CLIA), enzyme immunoassays, competitive 
protein binding assays, and automated chemiluninescence protein-binding assays (66).  
 
A recent study compared three available assays: HPLC-APCI-MS (HPLC-atmospheric 
pressure ionization-mass spectrometry), RIA (IDS, UK) and CLIA (LIAISON, Diasorin) 
(Figure 7) (63). In the same set of samples the mean 25(OH)D concentrations were 85 nmol/L, 
70 nmol/L, and 60 nmol/L measured by HPLC, RIA and CLIA, respectively (63). Thus, the 
difference between HPLC and RIA values was 14.8 nmol/L, and between HPLC and CLIA – 
24.5 nmol/L. Both HPLC-APCI-MS and CLIA were evaluated and approved by Vitamin D 
External Quality Assessment Scheme (DEQAS), a program aimed to improve reliability of 
25(OH)D measurements (63;68). 
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Several other studies and data sets 
from DEQAS show large assay-specific 
variation (65-70). It is sometimes difficult to 
explain this variability, but it has been 
proposed that different methods may not 
recognize equally 25(OH)D2, 25(OH)D3 and 
some other recently discovered metabolites, 
such as 3-epi-25-hydroxyvitamin D (3-epi-
25(OH)D) present in samples from infants 
(64;69). This may lead to both false-positive 
and false-negative results, and difficulties in 
clinical interpretation (64). The majority of 
methods have a tendency to underestimate the 
actual vitamin D status. Thus, a measured 
25(OH)D  100 nmol/L may only ensure that 
the patient has serum 25(OH)D  80 nmol/L 
(67;69).    
 
To guarantee the accuracy of available 
25(OH)D assays the National Institute of 
Standards and Technology (NIST, USA)  has 
recently developed a reference material for 
circulating 25(OH)D (SRM 972) (69). It 
consists of 4 pools of frozen serum with 
different concentrations of 25(OH)D2, 
25(OH)D3, or both. The fourth pool 
additionally contains 3-epi-25(OH)D3 (69).  
 
Thus, it seems possible to standardize the methods used in different laboratories to one 
reference material and get analysis certification by NIST. In the nearest future several methods 
will be validated according to the NIST procedure, and their reliability will be improved, but to 
date LC-MS/MS and HPLC seem to be the most reliable methods for 25(OH)D assessment  
(65;70;71). Although these methods require more expensive equipment and take considerably 
longer time, they provide accurate quantitative measurements of both 25(OH)D2 and 
25(OH)D3 (71).  Immunoassays may have enough sensitivity to recognize low vitamin D status, 
however, they may be imprecise in estimation of  high serum 25(OH)D values (71). Some 
methods do not separate D2 and D3 forms and evaluate a sum of 25(OH)D2 and 25(OH)D3. 
These methods often have lower sensitivity for 25(OH)D2 than for 25(OH)D3, and 
underestimate the total 25(OH)D2 (64;67;69;71). In cases when vitamin D2 is not available in 
food or supplements, it may be of minor importance. In contrast, high dose supplementation 
(30,000 IU, AFI-D2 forte) available in Norway is a vitamin D2 form, and the evaluation of the 
effect of supplementation may largely depend on the method chosen for serum 25(OH)D 
assessment. 
 
 
Figure 7. Prevalence of vitamin D 
deficiency, insufficiency, and sufficiency in 
the same population according to HPLC, 
RIA, and CLIA measurements (63).  
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5.2. Serum 25-hydroxyvitamin D concentrations 
The lack of uniform terminology and classification system makes it very difficult to define the 
categories of vitamin D status. According a classification proposed by Holick, vitamin D 
deficiency should be defined as serum 25(OH)D levels < 50 nmol/L, vitmin D insufficiency as 
50-74 nmol/L, and vitamin D sufficiency as values  75 nmol/L (Figure 8) (61). Other authors 
proposed different thresholds for vitamin D deficiency and insufficiency, but mainly setting 
the threshold at 50 nmol/L (27;72;73). 
 
5.2.1. The cut-off for vitamin D deficiency 
was mainly chosen based on classical vitamin D 
actions on mineral homeostasis. Serum 
25(OH)D levels < 50 nmol/L are associated 
with mineralization defects, such as rickets in 
infants and children and osteomalacia in adults. 
On the other hand, several studies suggest that 
levels < 80 nmol/L may be related to impaired 
calcium absorption, lower bone mineral density 
(BMD) and osteoporosis  (74;75). Thus, the 
cut-off 50 nmol/L may be too low even in 
regard to bone health.  
 
5.2.2. Recommended vitamin D status. A 
panel of 25 world famous vitamin D researchers 
recommended that the serum 25(OH)D 
concentrations should be at least  75 nmol/L 
(30 ng/ml) in order to provide optimal health 
outcomes (76). Since most of the methods 
underestimate serum 25(OH)D concentrations 
(67;69), choosing this cut-off ensures that the 
true 25(OH)D values are > 50 noml/L (67). 
Serum 25(OH)D levels < 75 nmol/L may be 
considered as low (72).  
 
The threshold of 75 nmol/L was chosen based mostly on two considerations: serum 
PTH concentrations and non-classical effects of vitamin D (76).  
 
One of the main roles of PTH in vitamin D metabolism is to maintain serum 
1,25(OH)2D and calcium values in the normal range in the setting of low serum 25(OH)D 
concentrations. Serum 25(OH)D correlates negatively with serum PTH, and PTH increases 
with decreasing serum 25(OH)D (61). High PTH increases the activity of renal 1 –
hydroxylase that leads to increased 1,25(OH)2D production by kidneys. However, secondary 
hyperpatathyroidism (sHPT) caused by low 25(OH)D may result in low BMD, osteoporosis 
and high risk of fractures (77). Serum 25(OH)D concentrations  75 nmol/L suppress serum 
PTH levels maximally and provide optimal calcium absorption (72;78). At the same time some 
studies reported different thresholds for maximal PTH suppression in the range between 50 
and 80 nmol/L (79), and in some studies the relationship between serum 25(OH)D and PTH 
 
Figure 8. Vitamin D status (61). 
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appeared to be linear (80;81). These findings indicate that optimal range of serum 25(OH)D 
concentrations may differ between individuals. Moreover, racial differences in the relationship 
between vitamin D status, serum PTH and bone mineral density have been recently observed 
(79;80). A number of studies suggest that an optimal level of serum 25(OH)D may be different 
for Caucasians and non-Caucasians, since blacks increase PTH at 25(OH)D levels of about 50 
nmol/L (79;80). Furthermore, blacks seem to need lower 25(OH)D levels to maintain normal 
BMD (80). This suggests evolutionary developed differences in calcium homeostasis between 
races. Thus, it may be inappropriate to extrapolate directly the cut-offs for vitamin D 
deficiency and optimal vitamin D status developed for whites to other races and ethnic groups 
(80).  
 
Serum 25(OH)D concentrations > 75-80 nmol/L have been associated with decreased 
incidence of several common diseases, including cancer, autoimmune diseases, diabetes, 
cardiovascular events and total mortality (Figure 9) (76;82-91). These associations were 
proposed mainly on a basis of epidemiological studies of disease risk and outcomes in 
connection to pre-diagnostic vitamin D levels or surrogate measures of vitamin D status, such 
as UVB exposure and vitamin D intake (31;64;76). Experimental studies on cell lines and 
animal models support the hypothesis that the observed associations may by related to non-
classical actions of vitamin D (16;23;92;93)  
 
 
Figure 9. Disease incidence prevention by serum 25(OH)D in prospective studies (82-87;89-
91;94). 
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The effects of vitamin D supplementation on common diseases were further investigated in 
several randomized clinical trials (RCT). However, many of these studies turned to be 
inconclusive, possibly because the dose of vitamin D supplementation was too low to cause 
any significant improvement of vitamin D status (76;95;96). Nevertheless, some recent RCT 
have proven the beneficial effects of vitamin D supplementations on total mortality (RR 0.93; 
CI, 0.87-0.96) (meta-analysis of 18 RCT) (97), risk of wintertime influenza A in nursery 
school children (RR 0.58; CI, 0.34-0.99) (98), prevention of non-vertebral fractures (RR 0.80; 
CI, 0.72-0.89) (meta-analysis of 9 RCT, dose- dependent effect) (99), cancer risk (RR 0.2; CI, 
0.09-0.60) (Ca + D group) (100), risk of falls (RR 0.77; CI, 0.65-0.90) (101), and risk of 
cardio-vascular events (RR 0.90; CI, 0.77-1.05) (meta-analysis of 8 RCT) (102). In a large 
RCT on overweight and obese persons (103) vitamin D supplementation ameliorated 
symptoms of depression, but did not affect cardiovascular risk factors (104) and cytokine 
levels (105). Lack of effect of vitamin D supplementation on circulating cytokine levels was 
also reported by Yusupov et al. (106).  
 
5.2.3. Vitamin D deficiency syndrome (VDDS). Since vitamin D deficiency is often observed 
in patients with osteoporosis, chronic fatigue, chronic pain, depression, autoimmune diseases, 
diabetes, heart diseases, hypertension and certain cancer types, some researchers proposed to 
define a combination of these conditions as VDDS (107). This does not necessary mean that 
these diseases are caused by vitamin D deficiency, or that administration of vitamin D will 
cure them (107). VDDS is most probably a multifactorial disease with many contributing 
factors, but improvement of vitamin D status may possibly reduce the symptoms of VDDS.   
 
5.2.4. Toxic vitamin D status. Excessive UVB exposure does not cause any vitamin D 
intoxication, even though the exposure to 1 MED equals 10,000-25,000 IU of vitamin D 
supplementation (1;108). However, high doses of vitamin D supplementation (> 10,000 IU/d) 
may result in vitamin D intoxication associated with hypercalcemia (62;109;110). The most 
common symptoms of vitamin D intoxication are extreme pain due to kidney stone, vomiting, 
fever, chills, acute renal failure and any sings of dehydration related to hypercalcemia, such as 
conjunctivitis, increased thirst, constipation and hyporeflexia (109). The main biochemical 
findings of vitamin D intoxications are: hypercalcemia, hypercalciuria, secondary 
hypoparathyroidism and serum 25(OH)D concentrations > 280 nmol/L (109). The threshold 
serum 25(OH)D concentration for vitamin D toxicity, according to some researchers, may be 
in the range of 375-500 nmol/L (64;72). Moreover, few studies reported that a daily 
supplementation with 10,000 - 40,000 IU did not affect calcium methabolism, even though 
serum 25(OH)D may reach levels > 400 nmol/L  (111-113).  
 
5.3. Global vitamin D status  
According to recent meta-analysis on 394 cross-sectional studies with 32,266 subjects included 
from all over the world, the mean serum 25(OH)D levels was 54 nmol/L (114). Based on a cut-
off level of 75 nmol/L for serum 25(OH)D concentrations it has been estimated that over 80% 
of people, world-wide, have a low vitamin D status, and only 4 % were reported to have values 
>100 nmol/L (114). As it might be expected, Caucasians had higher 25(OH)D concentrations 
compared with non-Caucasians (Figure 10). The study also reported, significantly lower 
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serum 25(OH)D in children (<15 years) and older persons (>75 years) than in adults (15-75 
years), and slightly higher values in women compared to men, 56 nmol/L vs. 50 nmol/L, 
respectively (114).   
Depending on latitude, season, 
age and ethnical origin prevalence of 
vitamin D deficiency (serum 25(OH)D  
< 50 nmol/L) varies largely world-wide, 
being highest in non-Western 
developing countries (115;116).                                        
Serum 25(OH)D < 25 nmol/L (severe 
vitamin D deficiency) were most 
common in Sub-Saharan Africa, South 
Asia and Middle East regions (115). 
Despite of high UVB rates, up to 50% 
of populations living in these regions 
have serum 25(OH)D below the cut-off 
of 25 nmol/L (116;117). Some studies 
from Mongolia, China, Libanon, and 
Iran report high prevalence of severe 
vitamin D deficiency (10-60%) with a 
cut-off of 12.5 nmol/L (116).  
 
Although, vitamin D deficiency 
is less prevalent in Europe than in the 
above mentioned countries, the 
occurrence of serum 25(OH)D < 50 
nmol/L was reported to be 40-80% (118). The best vitamin D status in Europe was observed in 
the Nordic countries, including Norway (115;116;118;119). The mean serum 25(OH)D 
concentrations in Norway have often been reported to be within the range of 60-80 nmol/L 
(56;59;120-124). The prevalence of vitamin D deficiency among native Norwegians is about 
10-15 % (56), but may be as high as 40-50% during the winter (120).  Teenagers and elderly 
generally have high rates of vitamin D deficiency (40-80%). Although, serum 25(OH)D 
concentrations < 25 nmol/L are rare among native Norwegians, non-Western immigrants from 
Pakistan, Sri Lanka, Vetnam, Turkey and Somalia have an average serum 25(OH)D levels of 
~25nmol/L (121;123;124). Approximately 50-60 % of immigrants have concentrations < 25 
nmol/L, and, in 10-15% of them the levels are < 12.5 nmol/L (121;124).  
 
 
6. RISK FACTORS FOR LOW VITAMIN D STATUS 
 
A number of factors may contribute to the development of vitamin D deficiency. Little sun 
exposure or sun avoidance together with low vitamin D intake are definitely the main reasons 
(61;72;125). However, in certain circumstances other factors may be equally important. 
Impaired vitamin D absorption from the intestine may result in vitamin D deficiency, even 
under adequate vitamin D supplementation (126). The same applies for persons with excess 
body weight, but due to other reasons than malabsorption (127;128). Older persons, 
 
 Figure 10. Global vitamin D status (114). Data 
are means serum 25(OH)D concentrations.  
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individuals with dark skin, and persons with severe chronic diseases and kidney failure are also 
at risk of vitamin D deficiency (61;72;76).  
  
6.1. Sun exposure   
Season, latitude, time of day, atmospheric conditions, skin pigmentation, and sun exposure 
habits (sun avoiding behavior, clothing, sunscreens use) are among the factors that may affect 
vitamin D synthesis in the skin (1). 
 
6.1.1. Latitude and solar zenith angle. UVB fluence rates are highest at locations and times 
with low solar zenith angles (SZA), and decrease with increasing SZA (32;38;129;130). Thus, 
the UVB intensity is highest at equator, and lowest at northern latitudes (32). The UVB fluence 
and UVD3/ UVEry also depend on ozone depletion (38). This means that higher amounts of 
vitamin D may be produced at the equator than at northern latitude (32;130).  
One might then expect to find a geographical gradient in vitamin D levels. However, a 
recent meta-analysis of 394 cross-sectional studies on vitamin D status at different latitudes 
(0o-80oN) showed no significant correlation between latitude and vitamin D status (114). It is 
worthwhile to mention that a north-south gradient  before multiple adjustments was observed 
in Caucasians (114). Previous studies revealed contradictory results (77;131). A strong 
negative association between vitamin D status and latitude was observed by Zittermann et al. 
(131), and a positive one by Lips at al. (77).  
The lack of latitude gradient in vitamin D status may be explained by differences in sun 
exposure habits, clothing, vitamin D intake from food and supplements, genetic factors, skin 
pigmentation, and methods used to determine vitamin D status (114).  
 
6.1.2. Seasonal variation. At latitudes > 40o more UVB is absorbed by the ozone layer due to 
large SZA (46;130;132;133). Thus, much less UVB is reaching the ground. In Oslo vitamin D 
production from the sunlight takes place only during the summer months (April-October), 
since during the winter sunlight contains almost no UVB (46;134).  
Due to this seasonal variation in annual UVB fluence rates, serum vitamin D levels also 
vary with the season (132;135;136). Highest vitamin D concentrations are observed between 
July and September, and lowest in February and March (120;128;132;137;138). The 
prevalence of vitamin D deficiency is high during the winter months (30-40 %), and in some 
groups of people, predisposed to low vitamin D, may reach 90-100 % (56;73). On the average, 
summer values are about 50% higher than winter concentrations, and normally are > 80 
nmol/L  (21;56;72;73;133;137;139-141).  Several recent studies reported that winter serum 
25(OH)D concentrations correlate positively with 25(OH)D values achieved at the end of the 
previous summer (138;140;142). Thus, it has been suggested that serum 25(OH)D 
concentrations > 80 nmol/L at the end of the summer are required to prevent against vitamin D 
deficiency (< 50 nmol/L) during the following winter (138;140). Moreover, summer values > 
100 nmol/L may maintain the winter concentrations > 70 nmol/L (142). Some individuals have 
a low vitamin D status even during the summer (120;128;140). Sun avoidance, sunscreen use, 
clothing, little time spend outside and lack of clear recommendations for sun exposure may 
have contributed to the low vitamin D status in these individuals (138;140;143).  
In order to achieve any optimal vitamin D status during the summer it has been 
recommended to expose 25 % of the body surface (hands, face and arms) to the sun in the 
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middle of the day to ¼ MED daily (33). However, this sun exposure can prevent only against 
vitamin D deficiency, and seems not to be enough to reach serum 25(OH)D concentrations > 
75 nmol/L (40). On the other hand, an exposure to 1.4 SED (~0.5 MED) every day during the 
summer in real life conditions (summer clothing) may result in serum 25(OH)D levels >80 
nmol/L (138). It has also been shown that women who spent on the average 4-6 hours every 
week outdoor during summer reached the serum 25(OH)D levels ~100 nmol/L (142). Working 
outdoors was also associated with a good vitamin D status at the end of the summer (Table 6. 
Part I) (144;145).  
Vacations to sunny countries may improve vitamin D status significantly, especially 
during winter months (142;146).  In the study by Osmancevic et al. serum 25(OH)D increased 
by almost 50 nmol/L after 15 days of climate therapy of psoriasis patients at Gran Canaria 
(146). Thus, after whole body exposure of total dose 166 SED serum 25(OH)D levels were on 
the average 105 nmol/L (146). 
 
6.1.3. Atmospheric conditions. A number of environmental factors may attenuate the fluence 
of UVB radiation, including total ozone, clouds, aerosols, surface reflectivity and low altitude 
(48;147-149). Thick cloud cover and ozone layer may reduce vitamin D synthesis even 
considerably at the equator (48). Snow cover may increase vitamin D production, since it 
reflects and scatters a large fraction of UVB (48). Most calculations for vitamin D synthesis 
are still performed for clear atmospheric conditions (148). Usually, planar horizontal geometry 
is used, but we have shown that vertical cylinder geometry will give different and more 
realistic results (46). 
Air pollution may also be associated with decreased vitamin D synthesis (143;150). 
The level of air pollution was negatively correlated to UVB irradiance at the ground surface in 
polluted areas, and positively associated with prevalence of low vitamin D status (150). 
 
6.1.4. Sun avoidance (clothing, shade, sunscreen use). A number of skin cancer prevention 
campaigns have been launched during the last decades. “SunSmart” is one of the most famous 
programs that was designed to educate people about skin cancer and the ways it may be 
prevented (151;152). The five key recommendations for sun protection from SunSmart are: 
slip (cover as much of the body with cloths as possible), slop (reapply sunscreen with SPF >30 
every 2 hours), slap (wear a broad-brimmed hat), seek (stay in the shade) and slide (wear 
wrap-around sunglasses) (151;152). Following all these recommendations may completely 
block vitamin D synthesis and result in vitamin D deficiency.  
 
 
6.1.4.1. Clothing. The amount of vitamin D produced in the skin is proportional to the area of 
uncovered skin exposed to UVB radiation (1). Whole body exposure is practically possible 
only in tanning units or UV cabinets, since hardly more than 50 % of the body surface may be 
exposed to the sun at the same time (146). During the summer about 65-80% of the body 
surface usually remains covered with cloths (1;40;125). But not even 20-35 % of remained 
uncovered skin is directly exposed to the sun due to the geometry of the body (49;125). Thus, 
typical summer clothes may minimize vitamin D synthesis to 10-25 % of what is maximally 
possible.  
 
 - 30 - 
6.1.4.2. Shade. When the influence of shade is taken into account, vitamin D production 
decreases further, especially in urban environments and nearby buildings (125). Thus, vitamin 
D deficiency is prevalent in urban areas (143;153;154). Shade reduces UVB fluence rates and 
vitamin D synthesis by approximately 60 % (155). It has been observed, that women who 
prefer to stay in the shade have 50% lower serum 25(OH)D concentrations (86 nmol/L) 
compared to women who prefer to stay in the sun (126 nmol/L) (142).  
 
6.1.4.3. Use of sunscreens may seriously 
interfere with cutaneous vitamin D 
synthesis, leading to low vitamin D status 
(157). Sunscreens absorb mainly UVB, 
but also some UVA (157;158).  Some 
studies have suggested that that use of 
sunscreen with sun protection factor (SPF) 
>8 may decrease vitamin D synthesis by 
90%, and with SPF > 15 by approximately 
95-99%  (159-161). However, most recent 
studies showed little or no effect of 
sunscreens on vitamin D synthesis 
(158;162;163). The most likely reason for 
this is that in most cases sunscreens are 
not properly applied and the level of sun 
protecting is much lower than labeled SPF 
(158;163). 
 
6.1.5. Skin pigmentation. The skin 
pigment melanin limits penetration of 
UVB radiation that results in low vitamin 
D synthesis in those persons (7). 
Individuals with skin type V and VI may 
need 5-10 times longer sun exposure than 
persons with skin type I and II in order to 
produce the same amount of vitamin D 
(108;164). Therefore, non-Caucasians 
usually have much lower vitamin D status than Caucasians, especially living at high latitudes 
(114). Blacks also have small seasonal variation of vitamin D (165).  
However, a paradox has been observed by Glass et al. (156). In a study performed on 
Caucasian women with skin types I-IV, the lowest vitamin D status was observed in women 
with skin types I and II (Figure 11) (156). The same trend was observed by others (142).A 
possible explanation for this finding is that persons with light skin are generally recommended 
to avoid sun and to wear sunscreens whenever they are outdoors.  
 
6.2. Vitamin D intake  
Dietary intake is an important source of vitamin D during the winter (73). Vitamin D may be 
obtained from food that naturally contain vitamin D, dietary products fortified with vitamin D 
 
Figure 11. Vitamin D status according to skin 
type (Caucasians, skin type I-IV (156), non-
Caucasians, skin type V-VI (114)).   
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and a variety of supplements (2;10). Since just few foods contain vitamin D in significant 
quantities, it might be very difficult to obtain adequate amounts of vitamin D only from food 
(56). Thus, supplementation may be needed during the part of the year when vitamin D cannot 
be produced in the skin.  
  
6.2.1. “Recommended” intake does not mean “adequate” intake. The recommended 
vitamin D intake in most European countries, including Norway, is about 10 μg (400 IU) for 
children and 5-7.5 μg (200-300 IU) for adults (55). According to a report of the National 
Nutrition Council, the total vitamin D intake from both food and supplements in Norway is 
very close to the one that was recommended and is 10-12 μg for adults, similar (9-10 μg) for 
small children and 5-6 μg for adolescents (56). However, the prevalence of vitamin D 
deficiency is still high (73;120).  
An intake of 400 IU may ensure that 97.5% of a population would maintain serum 
25(OH)D levels > 25 nmol/L, but only 50 % of persons would maintain levels > 50nmol/L 
(166;167). According to recent observational and experimental studies the increment in serum 
25(OH)D concentration after vitamin D supplementation is dependent the initial vitamin D 
status, and vary from 2.5 nmol/L per 100 IU of vitamin D intake in persons with low initial 
levels to 1.5 nmol/L or less for those with high serum 25(OH)D at baseline (9;78;88;168;169).  
Thus, supplementation with 400 IU/d may result in an increase of serum 25(OH)D by 6-10 
nmol/L, 1,000 IU/d in an increase by 15-25 nmol/L, and a daily supplementation with 2,000 IU 
should be enough to raise 25(OH)D by approximately 30-50 nmol/L. This is in agreement with 
most published studies (9;43;78;88;166;168-172), except one by Holvik et al. that showed an 
increase of serum 25(OH)D concentrations by 34 nmol/L after only 1 month of vitamin D 
supplementation with 400 IU/d (173). That was enough to reach serum 25(OH)D >75 nmol/L 
(173). Other studies suggested that an intake of 1,500-3,000 (76;82;168;171;172;174;175)  
may be required to reach serum 25(OH)D > 75 nmol/L, and at least 1,000 IU/d may be needed 
to maintain vitamin D status at this level (166;167). Obese persons, persons with severe 
vitamin D deficiency and associated chronic diseases may require even higher doses of vitamin 
D supplementations (3,000-10,000 IU/d) (87;103;111;169;176).  
The effect of oral vitamin D supplementation to increase serum 25(OH)D 
concentrations is also dependent on intestinal absorption of vitamin D. Thus, malabsorbtion 
syndrome as a consequence of chronic inflammatory diseases (Chron’s disease, cystic fibrosis, 
short bowel syndrome) or pancreatic insufficiency may diminish effects of oral 
supplementation (126;177). In persons with decreased vitamin D absorption from the intestine 
single annual intramuscular injections of a “mega dose” of 600,000 IU may be preferred 
(178;179). This method of administration results in fast increase of serum 25(OH)D to the 
maximum values of 100-120 nmol/L during the first 6 months (178;179).  
 
6.2.2. Vitamin D3 or D2? Vitamin D supplementation is available in two forms. The major 
preparation used in Norway is vitamin D2 (AFI-D2 forte) (Table 2). Although vitamin D2 and 
vitamin D3 supplementation is regarded as equally potent and used to be administrated in the 
same doses, several studies have questioned their equivalency (5;180-183). A number of 
studies suggested that vitamin D3 supplementation is 2-3-fold more effective to increase serum 
25(OH)D concentrations than vitamin D2 (180;183-185). Moreover, serum 25(OH)D levels 
seem to decay much faster after D2 administration compared to D3 administration (181). 
Relatively, the low potency of vitamin D2 supplementation was explained by diminished 
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binding of vitamin D2 metabolites to BDP and short half-life (17;180). It is also possible that 
some methods used for serum 25(OH)D measurements may have underestimated the 
concentrations of vitamin D2 metabolites due to low sensitivity (64;67;69;71). However, a 
recent study investigated the effect of vitamin D2 and D3 supplementation (1,000 IU/d for 11 
weeks) on serum 25(OH)D increase using one of the most reliable methods (LC-MS), and 
concluded that vitamin D2 and vitamin D3 are equally potent to improve vitamin D status (5). 
Unfortunately, the study did not have a follow up to asses the decay of serum 25(OH)D 
concentrations after the end of the intervention. Similar 25(OH)D increases after 
administration of 1.25 mg D2 or D3 was also observed by Thacher et al. in a study performed 
on Nigerian children (182). Thus, further research might be needed to clarify possible 
differences in vitamin D2 and D3 bioavailability. 
 
6.3. Excess body weight  
During the last decades the prevalence of overweight (BMI 25-30 kg/m2) and obesity (BMI > 
30 kg/m2) in Norway has followed the global trend and increased dramatically, reaching 
epidemic proportions (186;187). Just between 1990 and 2001 the prevalence of obesity   
increased from 4% to 11% for women and 5% to 13% for men (186). The average BMI in the 
adult Norwegian population has also increased significantly over these years and is above the 
upper limit of a normal BMI range (BMI 18.5-24.9 kg/m2) (186;187). The increase of body 
weight is accompanied by increased risks of negative health outcomes and associated diseases 
(188). Vitamin D altered metabolism and vitamin D-related disorders are among these 
(132;176;189-198). 
 
6.3.1. Serum 25(OH)D values decrease proportionally with increasing BMI (128;189;199). 
Thus, an increase of 1 kg/m2 in BMI is associated with a decrease in serum 25(OH)D 
concentration by 0.7-1.3 nmol/L (128;189;199;200). Consequently, persons with normal 
weight have on the average about 20-25 nmol/L higher serum 25(OH)D concentrations than 
persons with BMI > 40 kg/m2 (morbid obesity) (128;201). The prevalence of vitamin D 
deficiency in morbidly obese persons was reported to be 60-80%, that is 2-3-fold higher than 
in non-obese individuals, and 4-6-fold higher than in normal weight subjects (56;202-204). 
Obese persons commonly have low seasonal variation of serum 25(OH)D concentrations, and 
often do not reach the threshold of 75 nmol/L even during the summer (128;196). As a result 
of vitamin D deficiency sHPT is often observed in overweight and obese persons (191;200).  
 
6.3.2. Serum 1,25(OH)2D concentrations. Earlier studies reported elevated serum 
1,25(OH)2D values in subjects with high BMI related to high prevalence of sPTH 
(197;198;205;206). However, recent studies observed a negative correlation of serum 
1,25(OH)2D with BMI and adiposity, and a positive one with serum 25(OH)D 
(120;133;194;200;207). Thus, an increase of 1 kg/m2 in BMI resulted in 0.8-0.9 pmol/l 
decrease of serum 1,25(OH)2D concentrations (194;195). This supports the hypothesis that 
renal 1,25(OH)2D synthesis is dependent not only on PTH levels, but also on substrate 
concentrations.  
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6.3.3. Influence of excess body weight on vitamin D status  
6.3.3.1. Sequestration in fat tissue. Vitamin D is a fat-soluble compound, thus, it accumulates 
in the excess body fat and muscular tissue, and, therefore, has reduced bioavailability in 
overweight  and obese individuals (190). As was calculated on the basis of an animal model 
(pigs), a woman of 70 kg with fat mass of 35 % (normal weight) would store almost three-
quarters of the total vitamin D in the fat tissue, but 25(OH)D would be more equally 
distributed in the body: 35 % in fat, 30 % in serum, 20 % in muscles, and 15 %  in all other 
tissues (208). Therefore, it is also likely that serum concentrations of vitamin D metabolites 
may be affected by a large overall volume of distribution (110).  
 
6.3.3.2. Sun exposure habits. Other factors, such as sun exposure habits during the summer 
and diet composition, may also contribute to low vitamin D status in persons with excess body 
weight (194;196;209;210). Obese persons have reduced outdoor activity during the summer, 
and generally prefer to cover as much of the body with cloths as possible (196;209). Although 
they have a large skin surface and possible may produce more vitamin D than normal weight 
persons, the same sun exposure results in almost 60 % less increase in serum 25(OH)D 
concentrations in obese than in non-obese (190). The mechanism behind it is not fully 
understood, but it has been proposed that obese may have altered release of vitamin D 
produced in the skin into blood circulation, since subcutaneous fat may sequester more vitamin 
D. Supporting this hypothesis, vitamin D3 concentrations in subcutaneous fat tissue and serum 
were positively correlated in a pilot study on obese adults undergoing gastric bypass surgery 
(211).  
 
6.3.3.3. Inadequate vitamin D consumption.  Obese persons seem to benefit less from the 
same dose of oral vitamin D supplementation than non-obese persons (190;212). At the same 
time, they have generally decreased vitamin D intake compared with normal weight persons 
(210). A number of studies have investigated the effect of different doses of vitamin D 
supplementation in persons with excess body weight (127;176;190;212;213).  The general 
conclusion is that the efficiency of vitamin D supplementation to increase serum 25(OH)D 
concentrations is dependent on BMI, and that higher doses of supplementation are required in 
obese persons than in normal weight subjects to reach and maintain optimal vitamin D status 
(212;213). In a study of Zittermann et al. vitamin D3 supplementation with 3,300 IU/d for 1 
year in patients with BMI > 27 kg/m2 resulted in an increase of serum 25(OH)D by 56 nml/L, 
and was efficient in giving 25(OH)D concentrations > 80 nmol/L (176). For persons with BMI 
> 40 kg/m2 a supplementation with 40,000 IU per week may be necessary in order to reach 
serum 25(OH)D >80 nmol/L (127).  
 
6.3.4. Does vitamin D deficiency cause obesity? Adipocytes express both VDR and 1-
hydroxylase and may convert 25(OH)D to 1,25(OH)2D (214;215). Experimental studies on 
adipose tissue cell lines confirmed the importance of  1,25(OH)2D in modulating adipocyte 
function by regulating apoptosis, adipose tissue fat depot location and glucorticoid production 
(215;216). Observational studies have also reported that serum 25(OH)D concentrations were 
associated with a number of metabolic risk factors (199;217-223).  Thus, vitamin D status was 
positively related to insulin sensitivity and negatively to fasting glucose, insulin levels, 
adiponectin concentrations and other markers of diabetes II type (waist circumference, 
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haemoglogin A1c) (199;217-223). Serum 25(OH)D concentrations were also associated with 
changes in lipid profile (220;221;223). Moreover, vitamin D intake with food and supplements 
was an independent predictor of obesity in the study performed by Kamycheva et al. (210).  
 Based on these findings, it has been proposed that vitamin D deficiency may play a 
role in development of common obesity (127;176;224;225).  Several studies were initiated to 
test this hypothesis, and to investigate if improvement of vitamin D status may result in weight 
loss (127;176;224). RCT revealed no effect of vitamin D supplementation on weight loss 
(127;176). On the other hand, weight loss was associated with improvement of vitamin D 
status (226). Thus, vitamin D deficiency seems to be a consequence of obesity, but not the 
other way around. However, vitamin D supplementation in obese persons may enhance the 
beneficial effects of weight-reduction programs, and may possibly improve metabolic, 
cardiovascular and mental health in these persons (103;176;226).  
 
6.4. Genetic variation and vitamin D status 
According to GWAS with about 34,000 persons from 15 European cohorts, the risk of vitamin 
D deficiency and insufficiency may be genetically determined (13). The genetic variations in 
three loci were identified to be associated with serum 25(OH)D levels (13;227). Among them 
are: 1) the locus of the gene coding the enzyme involved in cholesterol synthesis from 7-DHC 
(7-DHC-reductase), 2) CYP2R1, the gene that encodes the enzyme involved in the 
hydroxylation of vitamin D to 25(OH)D in the liver, and 3) GC that encodes DBP (13;227). 
The most unlucky combination of the genetic variants (all three loci associated with low 
vitamin D status) was associated with a 2.5-fold higher risk of serum 25(OH)D < 75 nmol/L 
than the most lucky combination (none of the loci associated with low vitamin D status) (13). 
Moreover, genetic factors seem to explain about 50% of serum 25(OH)D variability during the 
summer, although, environmental factors may play a major role during the winter (21). Thus, 
testing gene polymorphism of the vitamin D associated loci may be useful to identify persons 
with high risk of vitamin D deficiency.  
 
6.5. Who is at risk for Vitamin D deficiency?  
There are several groups of people that are at high risk for vitamin D deficiency including 
infants, adolescents, elderly, vegetarians, non-Caucasians living at northern latitudes, skin type 
I and II individuals avoiding sun, overweight and obese, persons with malabsorbtion, and 
individuals using medications that may interfere with vitamin D endocrine system, such as   
anticonvulsants, rifampicin, cholestyramine, highly active antiretroviral treatment and 
glucocorticoids (61;72;76;228).   
Vitamin D deficiency should be checked for in children with symptoms common for 
rickets (pain, irritability, bone deformations, impaired growth) and often infections, as well as 
in adults with evidence of poor bone health (osteomalacia, osteopenia, low BMD, osteoporosis, 
fractures), chronic pain, proximal muscle weakness and fatigue (72;76;228). Recently it has 
been suggested that patients with depression, autoimmune diseases, diabetes, heart diseases, 
hypertension and cancer may also have vitamin D deficiency or VDDS (76;107). 
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7. VITAMIN D AND CANCER 
The role of vitamin D and its derivatives in cancer prevention and progression has been the 
topic of numerous recent investigations. It is evident that vitamin D may affect cancer risk and 
mortality, by action directly on cancer cells and by modulating anti-cancer immune responses 
(17;83;88). 1,25(OH)2D modulates a wide array of molecular reactions that result in anti-
proleferative, pro-differentiating, anti-inflammatory, anti-metastatic, pro-apoptotic,  and 
immunomodulatory effects (229;230). Colorectal (CRC), breast (BCa), and prostate cancers 
(PCa) are among the most studied malignancies in regard to vitamin D actions.   
 
7.1. Mechanisms of anti-cancer effects  
Most of cancer cells express VDR that mediates both genomic and non-genomic effects of 
vitamin D. CRC, BCa, and PCa cells also express 1-hydroxylase and may convert 25(OH)D 
to 1,25(OH)2D (16;231), and 24-hydroxylase that is responsible for vitamin D utilization and 
converts both 25(OH)D and 1,25(OH)2D to their less-active metabolites (17). The balance 
between these enzymes may be important for cancer development and prognosis. This also 
suggests that vitamin D supplementation and 24-hydroxylase-resistent analogs may possibly be 
used in cancer prevention and therapy (229). However, during cancer progression tumor cells 
often decrease expression of 1-hydroxylase and have reduced responds to VDR activation 
(232-234). At the same time, high expression of 24-hydroxylase was observed in cancer cells 
(232;233). 
  
7.1.1. Regulation of cell growth, proliferation, differentiation and apoptosis. Inhibition of 
cancer cell growth by 1,25(OH)2D most probably occurs due to cell cycle arrest and 
stimulation of apoptosis (230). In PCa cells 1,25(OH)2D treatment results in cell cycle arrest in 
G1/G0 phase, inhibition of cell proliferation, and decreased expression of the c-myc oncogene  
(235-237). In BCa cells 1,25(OH)2D facilitates apoptosis as well as expression of several key 
proteins involved in cell proliferation and differentiation (238;239). Both in vitro and in vivo 
studies show that 1,25(OH)2D has pronounced anti-proliferative and pro-differentiation effects 
on CRC (240;241). 
 
7.1.2. Regulation of androgen and estrogen receptor signaling. Growth of PCa and BCa 
cells is dependent on activation of androgen and estrogen receptor signaling pathways. 
1,25(OH)2D seems to be involved in regulation of both sex-steroid receptors (229). Thus, in 
BCa cells 1,25(OH)2D inhibits expression of estrogen receptors and decreases estrogen-
mediated cell proliferation (242). In PCa cells 1,25(OH)2D in general inhibits expression of 
androgen receptors, but in androgen-independent cell lines 1,25(OH)2D up-regulates 
expression of androgen receptors, and facilitates androgen-dependent anti-ptoliferative affects 
(236;243).  
 
7.1.3. Anti-inflammatory actions. In cancer cell lines, including PCa, BCa, CRC, 
1,25(OH)2D treatment gives anti-inflammatory effects like inhibition of prostaglandins 
synthesis, modulation of cycloxygenese-2, 15-hydroxyprostaglandin dehydrogenase, 
prostaglandin receptors and prostagalngin pathway genes; inhibition of  stress-activated kinase 
signaling and induction of MAP kinase phosphatase 5; inhibition of nuclear factor B 
activation and signaling; regulation of inflammatory cytokines production (229). 
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7.1.4. Inhibition of angiogenesis. In vivo and in vitro studies on BCa revealed that 
1,25(OH)2D inhibits expression of vascular endothelial growth factor (VEGF), the most active 
stimulator of angiogenesis, and decreases tumor visualization in mice (244). VEGF and matrix 
metallopeptidase-9 were also suppressed after 1,25(OH)2D treatment in a number of PCa cell 
lines (244;245). Moreover, tumors from VDR knockout mice had increased expression of 
VEGF, platelet-derived growth factor, and hypoxia-inducible transcription factor-1 (246). 
1,25(OH)2D was also shown to inhibit directly proliferation of endothelial cells (245;246). 
 
7.2. Observational studies 
A large amount of epidemiological data on the association of vitamin D status and cancer risk 
and mortality come from ecological studies that used surrogate measures of vitamin D status, 
such as UVB fluence rates, latitude, season, skin cancer incidence and dietary vitamin D intake 
(132;139;247-256). Grant conducted a multifactorial ecological study of cancer mortality rates 
in the United States using UVB fluence rates in July as a surrogate measure of the vitamin D 
status, and found nearly the same associations of “vitamin D status” with breast, colon, rectal, 
oesophageal, renal, stomach, gallbladder, pancreas, prostate cancers as well as with multiple 
myeloma and non-Hodgkin’s lymphoma (249), even thought these cancers have different 
contributing risk factors.  
Ecological studies have been accompanied by a large number of cohort, case-control, 
and cross-sectional studies aimed to shed light on the direct association between vitamin D and 
cancer. Most attention was concentrated around common cancer types such as CRC, BCa, and 
PCa. Due to a large number of studies and the discrepancy between them it seems more 
reliable to draw conclusions from meta-analysis of the observational studies recently 
performed. 
 
7.2.1. Colorectal cancer (CRC). According to meta-analysis by Gandini et al., there is a 
consistent inverse correlation between serum 25(OH)D concentrations and risk for colorectal 
cancer (257).  Based on 9 studies that included 2,630 cases, the summary RR for colorectal 
cancer was 0.85 (CI, 0.79-0.91) for 25 nmol/L. This is in agreement with earlier published 
mata-analysis by Yin et al., that reported the summary OR for colon cancer 0.78 (CI, 0.54-
1.13), rectal cancer 0.41 (CI, 0.11-1.49), and for types both of cancers 0.57 (CI, 0.43-0.76) for 
50 nmol/L increase (89). Moreover, serum 25(OH)D concentrations at diagnosis and vitamin D 
intake were inversely correlated with colorectal cancer mortality (258;259).  
 
7.2.2. Breast cancer (BCa). In a meta-analysis by Yin et al. based on 9 publications, the RR 
of BCa for an increase of serum 25(OH)D by 50 nmol/L was 0.73 (CL, 0.60-0.88) (260). The 
reported association was weaker than earlier suggested (91). Garland et al. suggested similar 
associations between vitamin D status, breast and colorectal cancer (91). Thus, an increase of 
serum 25(OH)D concentrations from < 40 nmol/L to > 95 nmol/L was associated with 55-58 
% reduction in risk for both cancer types. Gandini et al. found no association between vitamin 
D status and BCa (RR 0.89 (CI, 0.81-0.98) for 25 nmol/L) in the pooled analysis of 10 studies 
(257).  
 
7.2.3. Prostate cancer (PCa). No association between vitamin D status and PCa risk was 
found in two recent meta-analysis (257;261). The summary RR was 0.99 (CI, 0.95-1.03) for 25 
nmol/L in the meta-analysis performed by Gandini et al. (257), and OR was 1.03 (CI, 0.96-
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1.11) for 25 nmol/L in the study by Yin et al. (261). One study that was included in both meta-
analyses reported a U-shape in the association between PCa risk and serum 25(OH)D 
concentration (262). Thus, the risk was highest for men with serum 25(OH)D values < 19 
nmol/L and > 80 nmol/L, and the lowest risk was reported for men with serum 25(OH)D 
concentrations within the range of 40-60 nmol/L. However, this finding is likely to be just an 
isolated observation, since the upper quartiles of 25(OH)D concentrations were the same as in 
other studies showing protective or no effect (257). Another meta-analysis has estimated the 
role of SNP of VDR in PCa risk based on 36 recent studies (263). The authors concluded that 
the Apal a allele was associated with decreased risk of PCa among Asians, and the Fokl f allele 
was weakly associated increase risk of PCa in Caucasians (263).  Improved PCa survival was 
observed for persons with pre-diagnostic serum 25(OH)D concentrations > 80 nmol/L (264). 
 
7.3. Clinical trials  
7.3.1. Vitamin D for cancer prevention. Clinical studies on cancer prevention have been 
conducted to investigate the effects of vitamin D supplementation on CRC and BCa risk 
(100;240;265).  Since cancer cells and cells within the tumor microenvironment may convert 
25(OH)D to 1,25(OH)2D, is it believed the increase of serum 25(OH)D concentrations after 
adequate vitamin D supplementation may result in local 1,25(OH)2D synthesis and thereby 
anti-proliferative effects. Additionally, 25(OH)D may also activate VDR.  
The Women Health Initiative (WHI) study investigated the effect of supplementation 
with 400 IU/d of vitamin D3 primarily to prevent fractures, but the secondary outcomes of the 
study were risks for BCa and CRC (266). Initial analysis revealed no association between 
vitamin D supplementation and cancer risk (267). However, the reanalysis of the data 
suggested that the effect of vitamin D on CRC risk may be modified by hormone-replacement 
therapy (265). Thus, protective effects of vitamin D against CRC were shown only for women 
who had no estrogen treatment during vitamin D intervention.  
A small pilot RCT in 92 men and women with a history of pathology-confirmed 
colorectal adenoma reported that vitamin D3 supplementation with 800 IU/d for 6 months 
resulted in increased differentiation of normal colorectal epithelial cells and normalization of 
the colorectal crypt proliferative zone (240). Thus, the study supported the role of vitamin D in 
CRC development.  
A large, placebo controlled, double-blind, 4-year longitudinal clinical trial in 
postmenopausal women with 1,100 IU/d vitamin D3 supplementation and/or calcium (1400-
1500 mg) reported 77 % decreased risk of getting any type of cancer in vitamin D+calcium 
arm compared with placebo arm (RR 0.23 CI, 0.09-0.60; P < 0.005) (100).  
 
7.3.2. Vitamin D for cancer treatment. Most anti-cancer clinical trials with vitamin D were 
conducted on PCa patients and used 1,25(OH)2D (268). Some studies also investigated the 
effectiveness of vitamin D supplementation and vitamin D analogues. 
 
7.3.2.1. Vitamin D3 supplementation. A small pilot study in 15 PCa patients reported that 
supplementation with 2,000 IU vitamin D3 for 21 months prolonged the doubling time of 
prostate-specific antigen (PSA), an important marker of tumor growth (269). 
 A recent Phase II study in metastatic BCa patients revealed no effects of vitamin D3 
supplementation in dose of 10,000 IU/d for 4 months on palliative outcomes or prognosis of 
advanced BCa (111).  
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7.3.2.2. 1,25-dihydroxyvitamin D. Administration of 1,25(OH)2D alone or in combination with 
standard cancer therapy was reported in clinical trials on PCa. Although, some regimens of 
1,25(OH)2D treatment may result in hypercalcemia, the intermittent administration with high 
doses given 3 times a week or once a week was shown to be safe and resulted only in transient 
hypercalcemia and rare renal stones (270;271). The effect of the treatment was often evaluated 
based on serum PSA levels and overall survival (270). 1,25(OH)2D was in most cases used in 
combination with dexamathasone, paclitaxel, or carboplatin (272). 
 High-dose oral 1,25(OH)2D administration together with dexamethasone and 
carboplastin, or dexamethasone alone in PCa patients resulted in significant PSA decrease (two 
Phase II trials) (271;273). However, these results were not confirmed by ASCENT I clinical 
trial conducted in advanced PCa patients that observed almost no effect of 1,25(OH)2D on 
PSA concentrations  (274). 1,25(OH)2D was administrated in formulation of DN-101 
(Novacea) orally once a week together with taxotere and resulted in significant improvement 
of overall survival. Based on inspiring results of ASCENT I, a large Phase III (ASCENT II) 
was initiated (275).  ASCENT II had two arms: 1. docetaxel (new regimen, once every 3 
weeks) as a control arm, and 2. docetaxel (old regimen, once a week) + DN-101. 
Unfortunately, this study was stopped due to excess mortality in the study arm. At first, it was 
explained by possible 1,25(OH)2D toxicity, but further analysis of the results suggested that 
the excess mortality was caused by asymmetric study design and less effective docetaxel 
regimen in the study arm (275).  
 
7.3.2.3. Vitamin D analogs. Development of less hypercalcemic analogs of 1,25(OH)2D may 
solve the problem of administration of active vitamin D metabolites in high enough doses to 
cause therapeutic effects. Recently several 1,25(OH)2D analogues became available including  
EB1089 (seocalcitol), 1--vitamin D2, inecalcitol, and paricalcitol (229;276).  
 
Conclusion. Although the epidemiological data firmly show an association between serum 
25(OH)D concentrations, vitamin D intake, and solar radiation, the lack of well designed Phase 
II and Phase III  RCT makes it difficult to define a biologically optimal dose and TUL for 
vitamin D intake. At this moment there are over 300 open intervention studies that have been 
initiated to investigate the effect of vitamin D on cancer incidence and mortality (277). Thus, 
in the nearest future we will hopefully have answers to many of our questions.  
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8. GENERAL METODOLOGICAL CONSIDERATIONS 
8.1. Analysis data base  
Data on overweight and obese persons were provided by a Metabolic and Medical Lifestyle 
Management Clinic in Oslo, Norway, collected from September 2001 to January 2007. It 
contained data on serum 25(OH)D and 1,25(OH)2D concentrations, body composition 
parameters (BMI, body weight, fat mass, adiposity), season of blood sampling, gender, age and 
primary diagnosis in 1779 adults  (1464 women and 315 men) and 102 children (70 girls and 
32 boys). Data on co-morbidities were also recorded in the database (Paper 2 and 3).  
 
8.2. Volunteers  
To avoid any contribution from solar radiation, intervention studies were conducted during the 
winter months (November to March), a time of the year when no vitamin D is synthesized in 
skin by sun exposure at our latitudes. 
 A total of 54 healthy volunteers (15 men and 39 women), aged between 21 and 65 
years, were included in the interventional studies (Paper 4 and 5). All volunteers were living in 
Oslo (59°N). Almost all participants (>90 %) were Caucasians and had Fitzpatrick skin types 
II or III. The participants were asked to fill out questionnaires that screened for: age, weigh, 
height, skin type, sun exposure, indoor tanning habits, and food. 
Exclusion criteria were: presence of severe disorders and medical conditions known to 
effect vitamin D status; pregnancy or plans to become pregnant; high-dose vitamin D 
supplementation, winter vacations to southern latitudes and indoor tanning late than 8 weeks 
before initiation of the study or plans for traveling to southern latitudes during the study.   
 
8.3. Serum 25(OH)D and 1,25(OH)2D assays   
 Serum 25(OH)D and 1,25(OH)2D in overweight and obese persons were analyzed at the 
Hormone Laboratory, Aker University Hospital and Fürst Laboratories, but by 
radioimmunoassays (RIA) (DiaSorin, Stillwater, MN, USA). Vitamin D deficiency was 
defined as serum 25(OH)D < 50nmol/L and vitamin D sufficiency as concentrations  75 
nmol/L (Paper 1, 2, and 3). 
 
 Serum 25(OH)D of 54 volunteers, participated in intervention studies, were analyzed at 
the Haukeland University Hospital, Bergen, Norway.  The 25(OH)D assay was performed 
by LC-MS method (LC MSD SL; Agilent Technology, CA). The mean recovery of 
calcidiol was 77.2% (SD 3.9%) and the interassay variation was 4.9%, with a detection 
limit < 4 nmol/l (Paper 4 and 5). 
 
8.4. Body composition and BMI  
Body composition parameters and BMI were estimated using bioelectric impedance analysis
(BIA) with Tanita Body Fat Monitors, TBF 300 GS (Tanita Corp of America, USA) (Paper 2 
and 3). Overweight in adults was defined as a BMI in the range 25 – 29.9 kg/m2. Obesity and 
morbid obesity were defined as a BMI  30 kg/m2 and  40 kg/m2, respectively. In children 
and adolescents obesity and overweight categories were defined based on specific centile 
curves standardized for age and sex (Paper 3). Overweight was defined as a BMI between the 
85th and 95th percentiles. Obesity was defined as a BMI  95th percentile. 
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8.5. Vitamin D intake  
Vitamin D intake of volunteers that participated in the intervention studies was analyzed based 
on food frequency questionnaires (Paper 4 and 5). No vitamin D intake or supplementation 
data were recorded in the database on overweight and obese persons (Paper 2 and 3). RDD of 
D3 has been increased in 2004 from 5 μg/d to 7.5 μg/d. D2 supplementation for adults was not 
available in Norway during the observation period.
8.6. UV exposure    
 Sources of UV radiation were commercially available and approved type 3 tanning units 
equipped with Solarium Super Plus 100 W tubes (2.0 % UVB280-320 nm, device S2) (Paper 
4), or with Golden Sun RS 100 W and Beauty Sun S 25 W spaghetti tubes (Wolff System, 
Basel, Switzerland) (2,15% UVB280-320 nm, device S3) (Paper 5). The spectral distributions 
of the lamps were provided by the producer (Figure 12). Additionally, fluence rates of 
both tanning units were measured using a UV-meter (Solar Light Company Inc.) (paper 4 
and 5). Emission spectra of S3 and of the sun (Oslo, 22 July 2010, 12.00 AM) were 
measured with a AvaSpec ULS fiber optic spectrometer using AvaSoft 7.3.1 (Avantes BV, 
NL-6961 RB Eerbeek, Netherlands) (Paper 5).  
 
 Efficiency spectra of vitamin D formation were calculated based on action spectra of 
previtamin D3 synthesis in the human skin (CIE-2006) (278). CIE erythema weighted UV 
doses are presented as Standard Erythema Dose (SED; 1 SED = 100 J/m2). One SED is 
equivalent to about 0.5 MED for the most sensitive type 1 skin (1 MED = 200 J/m2) (Paper 
4 and 5). 
8.7. Data analysis 
 In obese and overweight persons correlations between 25(OH)D, 1,25(OH)2D, BMI, 
adiposity, age were analyzed using SigmaPlot 10.0 and SPSS 15.00 for Windows (Paper 2 
and 3). The monthly data of the variables were presented as means ± SEM. Correlation 
analysis was also performed for 25(OH)D quartiles using one-way ANOVA and the 
Bonferroni correction. The alpha criterion for two-tailed statistical significance was 
defined < 0.05.   
 
 Data for healthy volunteers were analyzed using Sigma Plot 10.0 for Windows. The 
variables are presented as means ± SEM. The criterion for statistical significance is defined 
as P < 0.05. (Paper 4 and 5)  
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9. SUMMARY OF PUBLICATIONS 
Paper 1 
  
Obesity and increased risk of cancer: Does decrease of serum 25-hydroxyvitamin D level 
with increasing body mass index explain some of the association? 
Aims: Our earlier investigations suggest that serum 25(OH)D levels decrease with increasing 
BMI. At the same time, excess body weight is associated with increased risk of cancer.  Thus, 
we wanted to evaluate the possible connection between cancer risk, BMI and vitamin D status.  
Methods: In this study, we analyze data published in current meta-analysis, prospective 
studies, and systematic reviews on cancer-specific risk attributed to high BMI and low vitamin 
D status. 
Results: Our study suggests that a low vitamin D status may explain at least 20% of the cancer 
risk attributable to high BMI. The contribution of low 25(OH)D to the increased cancer risk 
with increasing BMI may be different for different cancer types. Thus, we find 40% for breast 
cancer, and 26 and 75% for colorectal cancer in men and women, respectively. 
 
Paper 2  
 
The serum 25-hydroxyvitamin D is a predictor of 1,25-dihydroxyvitamin D in overweight 
and obese patients. 
Aims: Although, it is generally accepted that serum 1,25(OH)2D concentrations remain almost 
constant in time, some groups of patients may have decreased 1,25(OH)2D concentrations. We 
aimed to investigated the factors that may directly influence serum 1,25(OH)2D 
concentrations.  
Methods: In the present study the associations between 25(OH)D, 1,25(OH)2D, BMI, body 
weight, fat mass, adiposity, season, gender and age were analyzed in 1779 obese and 
overweight  patients. 
Results: Serum 25(OH)D among the other studied factors was the strongest predictor for 
serum 1,25(OH)2D. The 1,25(OH)2D concentrations were 25.4 pmol/L (Cl, 19.3-31.5) lower in 
the lowest 25(OH)D quartile to compared with highest quartile. A seasonal variation was 
observed for both vitamin D metabolites. Among all body composition parameters, adiposity 
had the strongest predictive power on serum 1,25(OH)2D concentrations. Serum 1,25(OH)2D 
concentrations were also associated with age. 
 
Paper 3 
 
Vitamin D status in Norwegian children and adolescents with excess body weight. 
 
Aims: The purpose of this study was to determine the prevalence of vitamin D deficiency and 
insufficiency in Norwegian children and adolescents with excess body weight. 
Methods: Vitamin D status and seasonal variations of 25(OH)D and 1,25(OH)2D were 
analyzed in 102 children and adolescents (70 girls and 32 boys), 8–19 yr of age, with 
overweight and obesity. 
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Results: Overall, 50% of the children and adolescents included in the study had vitamin D 
insufficiency and 19% had vitamin D deficiency. Only 42% of teenagers had 25(OH)D levels 
75 nmol/L vs. 72% of preteens. Serum 25(OH)D concentrations had a typical seasonal 
variation with the highest values observed during the summer. In contrast, serum 1,25(OH)2D 
had a peak during the spring. 
 
Paper 4 
 
Sunbeds as vitamin D sources. 
 
Aims: We wanted to determine whether repeated exposures to small UV doses from a 
commercial sun bed are efficient to increased serum 25(OH)D concentrations. We also aimed 
to investigate the impact of initial vitamin D status on serum 25(OH)D increase. 
Methods: Healthy volunteers were randomly divided into two groups that had different 
tanning regimens: 6.75 MED and 13.5 MED (Sun2 device). 
Results: The mean 25(OH)D values after exposure were ~80 nmol/L and the mean  increase 
(~15 nmol/L) was the same for all UV doses given. Persons with the lowest initial levels got 
the largest increase. The level in this group was back to the pre-exposure level after 2–4 weeks.  
 
 
Paper 5 
 
Effect of vitamin D supplementation and ultraviolet B exposure on serum 25-
hydroxyvitamin D concentrations in healthy volunteers. 
 
Aims: The aim of the present study was to compare the efficiency of oral vitamin D 
supplementation and multiple UVB exposures for improvement of the vitamin D status. 
Methods: Healthy volunteers were randomly divided into two groups. Group 1 started with 
vitamin D supplementation (2,000 IU/d for 30 days) and continued with 10 Sun3 exposures. 
Group 2 started with 10 Sun3 exposures and continued with vitamin d supplementation. 
Results: Oral supplementation with vitamin D3 was slightly more beneficial than UV exposure 
(10 Sun3 exposures of total dose 23.8 SED; vitamin D weighted dose: 134 J/m2 per 1 SED). 
The first phase of intervention resulted in an increase of serum 25(OH)D concentrations by 
~25 nmol/L. The total serum 25(OH)D increase after both interventions in both groups was 
31.3 nmol/L (SEM ± 3.8 nmol/L; P<0.001). At the end of the study 61% of the volunteers had 
serum 25(OH)D  75 nmol/L. The results of our study indicate that daily whole body sun 
exposure at ~0.5 SED may be enough to achieve and maintain serum 25(OH)D concentrations 
 75 nmol/L, if the initial serum 25(OH)D concentrations are  50 nmol/L. This dose almost 
equals to 2000 IU/d of oral vitamin D supplementation, and about 2 hours per week of sun 
exposure to 1/3 skin surface area at Oslo latitude around midday during the summer.  
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10. DISCUSSION 
10.1. Vitamin D and artificial UVB sources 
Sun is the most efficient natural source of vitamin D. Thus, sun exposure during the summer 
may provide essential amounts of vitamin D3, some of which is stored for the coming winter 
(61). The serum 25(OH)D levels > 80 nmol/L at the end of the summer are considered 
necessary to avoid vitamin D deficiency (25(OH)D < 50 nmol/L) during the winter (140). 
However, it is not clear how much sun exposure is needed for optimal vitamin D synthesis 
(125). According to Holick’s rule, exposure of ¼ body skin surface to the sun for ¼ MED 
(~0.5-0.8 SED) is required to produce enough vitamin D, and is equal to 1,000 IU/d oral 
vitamin D (33). Recent studies examining serum 25(OH)D concentrations at the end of the 
summer or after controlled UVB exposure do not support this advice (125). It seems that 
longer sun exposures may be needed to reach an optimal vitamin D status, and the 
recommended exposure is probably enough just to prevent vitamin D deficiency during the 
summer (40;140). For people living in urban areas even the current advice seems to be difficult 
to follow. It is not always possible for them to incorporate “sunshine minutes” into daily 
working schedule, since the best exposure time is the midday (44;46). Thus, vitamin D 
deficiency is prevalent even in the sunny countries (115;279). 
   
10.1.1. How much vitamin D do we get from the sun? At northern latitudes vitamin D 
synthesis takes place only during the summer months (April-October). Therefore, serum 
25(OH)D concentrations vary during the year, usually in the range of 50-80 nmol/L, with a 
peak in July-September, and a nadir in February-March . Sun exposure habits during the 
summer may contribute significantly to seasonal variation of vitamin D. The time spend 
outdoors during the summer and the area of uncovered skin surface exposed to the sun 
correlate positively with serum 25(OH)D concentrations (142;145).  
Thieden et al. (138) estimated vitamin D status and summer sun exposure behavior in 
Danish indoor and outdoor (gardeners) workers, and found that serum 25(OH)D concentrations 
were associated with the cumulative UVR dose obtained during the summer (mean: 156 SED), 
daily time spend outdoors (mean: 1.4 SED), number of days with large body surface exposed 
to the sun (upper body) (mean: 24 days), and constitutive pigmentation. (Table 5. Part I). Sun 
exposure for 1.4 SED/d (~16 minutes for Oslo) during the summer is enough to reach the 
25(OH)D levels > 80nmol/L at the end of the summer, and to maintain serum 25(OH)D > 50 
nmol/L during the winter.  
This is in agreement with a recent study (140) that estimated sun exposure behavior and 
seasonal variation of vitamin D in a UK population. During spring and summer the average 
daily sun exposure was ~0.5 SED (6 minutes for Oslo), which is close to that suggested by 
Holick as an optimal exposure for vitamin D synthesis. This dose was not enough to reach the 
threshold for vitamin D sufficiency (25(OH)D  75 nmol/L) at the end of the summer (140). 
Burgaz. et al. observed a large difference between serum 25(OH)D concentrations in 
two groups of women with different sun exposure habits. Women who during the summer 
preferred to stay in the sun instead of in shade, had skin type III or IV, and of normal weight, 
had 64 nmol/L higher serum 25(OH)D concentrations than women that preferred shade, had 
skin type I or II, and were obese (142) (Table 5. Part I). The results of the study also 
suggested that the 25(OH)D levels > 100 nmol/L at the end of the summer may maintain serum 
25(OH)D > 75 nmol/L throughout the year (142). Vacations to sunny countries were also 
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associated with increased serum 25(OH)D concentrations. A woman who had 3 vacations to a 
sunny country during the winter had serum 25(OH)D levels of 139 nmol/L. A large increase in 
serum 25(OH)D concentrations (47 nmol/L) was observed in patients with psoriasis that 
received climate therapy in Gran Canaria (146;280). After a whole body sun exposure to a total 
dose of 166 SED over 15 days serum 25(OH)D values increased from 57 nmol/L to 105 
nmol/L (Table 5. Part I). Another study by Vähävihu et al. (281) reported an increase in 
serum 25(OH)D concentrations by 13.4 nmol/L (total dose 60 SED) and 24 nmol/L (total 
dose109 SED) after 2 weeks-climate therapy in Gran Canaria in patients with atopic dermatitis 
(281).  
 
 Persons working outdoors also seem to have a 
much better vitamin D status than indoor workers 
(144). Thus, in the study by Barger-Lux outdoor 
workers (landscaping, construction work, farming, 
and recreation) had serum 25(OH)D concentrations 
of 122 nmol/L (100-154 nmol/L), which decreased to 
74 nmol/L during the winter (145). The average time 
they spent outdoors was 38 hours per week (Table 5. 
Part I). The vitamin D status was dependent on the 
area of body skin surface that was uncovered during 
sun exposure. The skin area was calculated based on 
“Rule of nines” (Table 6).  
 
10.1.2. Do UVA-tanning units contain enough UVB for vitamin D synthesis? Even though 
modern tanning units are often called “UVA-sun beds” it does not mean they emit no UVB, 
but that they emit a lot of UVA. In fact, the tanning units allowed in Norway (CIE erythema 
weighted UV to 0.3 W/m2: 0.15 W/m2 of UVB and 0.15 W/m2 of UVA) emit slightly more 
UVB than sun at Oslo latitude during the summer (282). Thus, tanning devices may be useful 
to study the effects of solar UV exposure since it can be simulated under well controlled 
conditions. Our group has studied the efficiency of UVB radiation to provoke vitamin D 
synthesis using three different tanning units in regard to UVB emmission and intensity 
(43;52;283). In our first  study (283) we used lamps (Life Sun S 100W (device Sun1)) with the 
highest UVB content (UVB280-320 nm 3,9%). The two following studies were performed with 
lamps with almost 2-fold lower UVB content (device Sun2) (Paper 4), (device Sun3) (Paper 5). 
All studies were performed between October and April, a time of the year when vitamin D 
synthesis from the sun exposure does not occur.  
In general, the serum 25(OH)D increase was highest after exposure to a tanning unit 
with high UVB content (52;283). After 10 whole body exposures to S1 (total dose of 8.5 MED 
over 4 weeks) serum 25(OH)D concentrations increased on the average by 26 nmol/L, from 
initial levels of 65 nmol/L to 92 nmol/L (Table 5. Part II). After exposure to Sun2 and Sun3 
the increase in serum 25(OH)D concentrations was lower than for Sun1, but 25(OH)D and 
final vitamin D status were dependent on initial serum 25(OH)D concentrations (Paper 4). The 
mean increase after exposure to Sun2 was 15 nmol/L disregard of UV dose (6.75 MED or 13.5 
MED over 7 weeks). 
 Further, we aimed to compare the efficiency of oral vitamin D supplementation (2,000 
IU/d for 4 weeks) and 10 exposures to S3 (total dose of 23.8 SED (9 MED), to increase and 
Table 6. “Rule of nines” (145). 
 
Body area Skin 
surface, 
% 
Head  9 
Both arms  18 
Both legs  36 
Trunk 36 
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maintain serum 25(OH)D concentrations (Paper 5). Volunteers were randomized into two 
groups: Group 1 and Group 2. Group 1 received vitamin D supplementation at first and then 
continued with 10 whole body exposures. Group 2 started with 10 exposures and than 
continued with vitamin D supplementation. As in a previous study, serum 25(OH) increase 
was dependent on initial values. Thus, volunteers that did not have vitamin D deficiency after 
both interventions reached average concentrations of > 90 nmol/L. Vitamin D deficient 
participants also significantly increased serum 25(OH)D concentrations, although they did not 
reach the threshold of vitamin D sufficiency (Table 5. Part II). Vitamin D supplementation 
with 2,000 IU/d had almost the same effect on vitamin D status as 10 whole body exposures. 
The increase of serum 25(OH)D after first intervention was 25 nmol/L, and after both 
interventions 31 nmol/L on average.  
 The UV dose given in the study was equal to ~0.5 SED/d sun exposure to the whole 
body, or almost 1 MED to ¼ of body surface at Oslo latitude, that is about a 4-fold higher dose 
than previously recommended (33). Thus, our studies indicate that the recommended sun 
exposure is unlikely to be adequate for optimal vitamin D synthesis. Our findings are in 
agreement with other studies on the indoor tanning devices (Table 5. Part II). Rhodes el al. 
simulated the summer sun exposure by using a tanning device equipped with Arimed B and 
Cleo Natural lamps (5 % UVB). An exposure equal to 3.3 SED of solar UV dose (39 minutes 
in Manchester sun, UK) (36 minutes in Oslo sun) was given to 35 % of body surface (skin area 
that is usually stays uncovered during the summer) (40). After 18 exposures of a total dose of 
20 SED serum 25(OH)D concentrations increased significantly, but just to reach values > 50 
nmol/L. Only 26 % of participants had serum 25(OH)D > 75 nmol/L at the end of the study.  
 The results of the study conducted by Thieden et al. showed that even tanning units that 
emit only 0.5 % or 1.4 % UVB are efficient to induce vitamin D synthesis. However, only 
exposure to 1.4 % UVB devices resulted in substantial increase in serum 25(OH)D 
concentrations (41). After 8 exposures (total dose 253 mJ/cm2 of CIE vitamin D weighted UV 
(~21 SED) serum 25(OH)D concentrations increased by 30 nmol/L, reaching levels of 75 
nmol/L. The daily CIE vitamin D dose for this group was slightly higher than was given in our 
last study (140 J/m2 vs. 91 J/m2, respectively), and corresponds to 9 minutes of whole body sun 
exposure at Oslo latitude. In the 0.5 % UVB group serum 25(OH)D concentrations increased 
by 15 nmol/L (total dose 49 mJ/cm2 of CIE vitamin D weighted UV) (Table 5. Part II).  
 In contrast to other studies, Carbone at al. observed a large increase in serum 25(OH)D 
in volunteers exposed to 1.5% UVB tanning unit (total dose 20-40.5 SED over 12 weeks) 
(284). Just after 6 weeks serum 25(OH)D concentrations in participants with initial values < 75 
nmol/L increased by 60 nmol/L, and by 18 nmol/L in persons with initial concentrations  75 
nmol/L (Table 5. Part II).  
 
10.1.3. Broadband and narrowband UVB devises. Other sources of UVB radiation used for 
treatment of psoriasis and other skin diseases are broadband UVB lamps (BB-UVB) and 
narrowband UVB lamps (NB-UVB). These lamps have fluence rates in the region of 280-360 
nm, with a peak at 313 nm (BB-UVB) and of 311-313 nm (NB-UVB). In a number of recent 
studies both BB-UVB and NB-UVB were shown to induce significant vitamin D synthesis 
(Table 5. Part III) (164;285-293). The increase in serum 25(OH)D concentrations seems to be 
higher in the BB-UVB treated patients than in the NB-UVB treated patients. This might be due 
to the fact that spectra of NB-UVB lamps have a peak at 311-313 nm, while the maximal 
vitamin D synthesis occurs at wavelengths between 295 and 305 nm (39). Thus, BB-UVB 
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lamps cover most of the wavelengths required for vitamin D synthesis. The average increase of 
serum 25(OH)D concentrations for BB-UVB treated patients was 48 nmol/L, and for NB-UVB 
treated patients was 34 nmol/L (calculations are based on 8 published studies presented in 
Table 5. Part III). 
 
10.1.4. What is the most efficient source of vitamin D? NB-UVB and BB-UVB lamps are 
the most efficient sources of vitamin D. They emit mainly UVB of very high intensity, and 1 
MED dose may be achieved within few minutes of exposure (51).  
 The relative efficiency of other UVB sources to induce vitamin D synthesis varies with 
the ratio between UVEry and UVD, which practically reflects UVB content (42). Tanning units 
that emit 5 % UVB280-320 nm would most probably induce similar vitamin D synthesis as sun 
exposure at midday during the summer (UVD/UVEry = 1.7-1.8) (40;42;283). However, 
commercially available tanning units in Norway emit high doses of UVA and contain only 
about 2 % or less UVB280-320 nm (UVD/UVEry < 1.3) (282). That means that less vitamin D may 
be produced after exposure to the same UVEry dose in tanning units than in the sun at midday 
during the summer. The UVB content of the solar radiation also varies during the day, being 
highest at noon (46). Thus, the effects of available tanning devices to induce erythema and 
vitamin D synthesis are similar to that of solar radiation early in the morning (7-8 a.m.) and 
after noon (4-5 p.m.) (46). The action spectra of vitamin D, of erythema, and of melanogenesis 
are within the limits of error similar (44). The main possible difference is that the vitamin D 
spectrum has no significant value in UVA. Thus, tanning units are, as we have estimated, 
slightly, more erythemagenic than vitamin D-producing, although the differences are probably 
not significant. Thus, the efficiency of different UVB sources to induce vitamin D synthesis is 
as following: NB-UVB and BB-UVB > solar radiation between 8 a.m. and 4 p.m. during the 
summer > commercially available tanning devices. 
 
10.1.5. Indoor tanning and risk for cutaneous malignant melanoma (CMM). Several 
recent publications reported increased risk of CMM in indoor tanners (294). The OR presented 
by Lazovich et al. was 1.74 (CI, 1.42-2.14) for ever use of tanning facilities (295). A slightly 
lower RR for CMM in indoor tanners was found by Veierød et al. in Scandinavia (294). Earlier 
studies, however, do not support this, in spite of the fact that older tanning units were stronger 
than modern ones (282;296). Awareness about possible CMM risks should be high among sun 
bed users, especially those with fair-skin (skin type 1) (297). However, it is also possible that 
the risk of CMM for indoor tanners is overestimated due to other contributing factors, such as 
sunburns (298). A sun seeking behavior among these persons, recall bias present in 
retrospective studies.  
According to Lazovich et al., the risk of CMM was also higher for users of UVA-
emitting devices (OR 4.44; CI, 2.45-8.02) compared to UVB-enhanced units (OR 2.86; CI, 
2.03-4.03) (295). The Setlow’s CMM spectrum weights UVA strongly, which may support the 
epidemiological findings (299). However, the most recent CMM studies, using fish, transgenic 
mice, or monodelphis domestica, indicate that UVA has no melanomagenic effect (300-302). 
If these reports are correct and can be translated to humans, they argue against the recent 
reports of tanning units as CMM-generating devices. Two large meta-analyses also failed to 
show any significant positive correlation between use of tanning equipment and risk of CMM 
(RR 1.04 (CI, 0.91-1.14) (303) and RR 1.15 (CI, 1.00-1.31) (296)). Thus, the matter is still not 
scientifically solved.  
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10.2. Obesity and overweight are predictors of low vitamin D status 
Obesity is a known risk factor for vitamin D deficiency. The key mechanism behind that is 
possibly increased sequestration of fat-soluble vitamin D in a large volume of fat tissue 
(61;190;208;211). However, other factors, such as low sun exposure and inadequate vitamin D 
intake, may also contribute to low vitamin D status in overweight and obese persons 
(194;196;209;210). 
 Low serum 25(OH)D concentrations result in elevation of PTH and often in sHPT 
(10;14;211). That might be necessary to maintain serum 1,25(OH)2D concentrations high even 
in a setting of vitamin D deficiency. Supporting this theory, earlier investigations showed that 
persons with excess body weight had a low vitamin D status, but had high 1,25(OH)2D levels 
(197;198;205;206). We have conducted a study in over 2,000 overweight and obese persons 
registered in a Metabolic and Medical Lifestyle Management Clinic in Oslo between 
September 2001 and January 2007 (Paper 2 and 3). The aim of the study was to investigate 
possible predictors of serum 1,25(OH)2D concentrations, such as BMI, body composition, 
gender, age, season of blood sampling, and vitamin D status. The results of our study indicate 
that serum 25(OH)D may be the main predictor of serum 1,25(OH)2D in overweight and obese 
adults (Paper 2) (Figure 12). We further showed that a decrease in 25(OH)D by 1 nmol/L was 
associated with a decrease in 1,25(OH)2D concentrations by 0.4 pmol/L (P<0.001).  
 
 
Figure 13.  Serum 1,25(OH)2D concentrations 
(pmol/L) grouped according to 25(OH)D 
quartiles.  The box represents the 75th and 25th 
percentiles and the line within the box indicates 
the median quartile value. The whiskers 
correspond to minimum and maximum quartile 
values that are not classified as outliers. The 
circles above and below whiskers indicate 
outliers. The 1,25(OH)2D concentrations were 
highest in the highest  25(OH)D quartile (one-
way ANOVA p<0.001) 
            This is in agreement with other recent studies 
that report a significant positive correlation between 
serum 25(OH)D and 1,25(OH)2D 
(120;128;194;200;207). Moreover, an increase of 
serum 25(OH)D concentrations after UVB exposure 
or vitamin D supplementation led to a subsequent 
increase in serum 1,25(OH)2D concentration as well 
(146;182). These findings support the hypothesis 
that renal 1,25(OH)2D synthesis is dependent on the 
availability of 25(OH)D, which is its precursor 
However, this might be different for children and 
adolescents that do not seem to have any correlation 
between serum 25(OH)D and 1,25(OH)2D 
concentrations (Paper 3). 
              Despite of high prevalence of vitamin D 
deficiency in a teenage group (13-19 years), the 
highest serum 1,25(OH)2D levels were observed in 
adolescents  and the levels decreased significantly 
with age (Paper 2 and 3).This may at least in part be 
explained by age-related decrease in PTH capacity 
to induce expression of renal 1-hydroxylase (304), 
but may also be related to more strict regulation of 
renal 1,25(OH)2D synthesis in children than in 
adults, since stabile 1,25(OH)2D levels are essential 
during maximal bone growth (305). 
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 Excess body weight is also unlikely to affect serum 1,25(OH)2D concentrations in 
children and adolescents, but may be related to low vitamin D status (Paper 3). Our findings 
are in agreement with most studies in obese children (136;305-307). 
 In adults both 25(OH)D and 1,25(OH)2D concentrations are associated with adiposity, 
BMI, age, and varied with the season (Paper 2). Thus, persons with high BMI had both low 
vitamin D status and low 1,25(OH)2D concentrations (Table 7). Serum 25(OH)D 
concentrations were about 25-30 nmol/L higher during the summer than in the winter or early 
spring, with the highest values (> 80 nmol/L) observed in August. Serum 1,25(OH)2D 
concentrations had apeak in May and another one in September. Winter 1,25(OH)2D values 
were on the average 15 pmol/L lower than summer levels. The spring increase in 1,25(OH)2D 
may possibly be mediated by high PTH that usually shows a strong negative correlation with 
25(OH)D, and the second one occurred after the 25(OH)D increase and was possibly driven by 
that increase. Thus, serum 1,25(OH)2D concentrations are associated with a number of 
contributing factors which are closely related to each other, and may to a certain extent explain 
the 1,25(OH)2D variability. 
 
Table 7. Serum 25(OH)D and 1,25(OH)2D concentrations in normal weight, overweight, 
obese, and morbidly obese adults (age 20-80 years).             
 
 
25(OH)D, nmol/L 
 
BMI, kg/m2 
 
n 
 
1,25(OH)2D 
(± SEM), 
pmol/L 
 
Mean (±SEM) 
 
% < 50 
 
% < 75 
 
>100 
Men        
    < 25 31 117.1 (6.6) 82.9 (3.3) 0  38.7 19.4 
    25-29.9   76 109.9 (8.5) 74.4 (4.3) 19.7 55.3 18.2 
    > 30 208 100.3 (2.2) 64.0 (1.6) 27.4 71.2 6.7 
    > 40  44 97.3 (4.7) 52.9 (2.9) 43.2 93.1 2.3 
Women       
    < 25 177 116.3 (3.2) 82.6 (2.0) 9.1 42.9 27.0 
    25-29.9   402 111.8 (1.8) 76.7 (1.2) 13.7 47.8 15.7 
    > 30 887 102.2 (1.2) 69.5 (0.8) 20.9 62.3 11.3 
    > 40  158 97.9 (2.8) 65.1 (2.0) 27.2 68.0 8.2 
 
Vitamin D deficiency in children may be related to increased risk of MS, T1D, and 
asthma (305). In adults, a low vitamin D status may be associated with several common 
diseases, including cancer, autoimmune diseases, diabetes, cardiovascular events and total 
mortality (3;17;107). Based on our studies, we may conclude that since persons with excess 
body weight have high prevalence of vitamin D deficiency and insufficiency, they may also be 
more predisposed for the above mentioned diseases.  
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Moreover, a decrease serum 1,25(OH)2D may possibly also contribute to increased risk 
of cardiovascular diseases, diabetes, and renal failure in obese and overweight individuals 
(308). Interestingly, the best prognosis for cancer survival in our studies was observed for 
patients that were diagnosed with cancer during late summer and early autumn when both 
serum 25(OH)D and 1,25(OH)2D concentrations are high (139;251-256). 
 
10.3. Excess body weight, vitamin D, and cancer 
Body composition and BMI are important predictors of vitamin D status. Our earlier 
investigations suggested that 5 kg/m2 BMI increase was related to about 5 nmol/L decrease in 
serum 25(OH)D concentrations (128). Excess body weight is also associated with cancer 
incidence and mortality, with about 3-8 % of the total cancer incidence possibly being 
attributed to excess BMI (309;310).  
 
 In U.S. Health Professionals Follow-up Study Giovannucci et al. has observed that the 
risk of several types of cancer including PCa were modified by BMI and serum 25(OH)D (88), 
while BMI correlated negatively with 25(OH)D values. The study performed by Tuohimaa et 
al. revealed an interaction between methabolic syndrome factors, including BMI, vitamin D 
status, and PCa risk (311). Thus, the effect of metabolic factors on PCa risk was strongly 
conditioned by 25(OH)D levels.  
 Based on these finding, we proposed a hypothesis that the increased risk of cancer in 
persons with overweight and obesity may possibly be related to decreased serum 25(OH)D 
concentrations (Paper 1). Our calculations were performed based on current meta-analysis by 
Gorham et al. (312) and Garland at el. (313) that reported 50-55 % decrease in CRC and BCa 
risk with 55 nmol/L 25(OH)D increase, and the assumption that the effect of vitamin D status 
may be similar in all vitamin D-sensitive cancer types (Paper 1).   
According to our calculations, low serum 25(OH)D concentrations may explain 
approximately 20 % of total cancer risk attributed to high BMI. However, the contribution of 
vitamin D status to obesity-related cancer risk may vary with cancer type, probably being 
highest for CRC in women and BCa (Paper 1). Supporting our hypothesis, poor BCa outcomes 
and survival were linked to low vitamin D concentrations as a consequence of excess body 
weight in the study of Tsvetkova et al. (314). The authors evaluated the relationship between 
vitamin D and obesity-related factors in RCT of BCa adjuvant chemotherapy, and concluded 
that serum 25(OH)D concentrations were associated with key obesity-related factors, season of 
blood sampling, and race (314). Nonetheless, the prognostic effects of obesity-attributed low 
vitamin D status cannot be evaluated yet, since the follow-up of the study is not completed.   
 An interesting observation was reported by Yu et al. who investigated the effect of 
dietary vitamin D3 on endometrial cancer (ECa) development in mice (92). Animals were fed 
high-caloric diet to induce obesity, and the study group got diet additionally fortified with 
vitamin D3. Obese mice had increased risk of ECa, which was modified by vitamin D. Dietary 
vitamin D inhibited the carcinogenic effect of obesity on ECa, and was associated with 25 % 
reduction in incidence of endometrial pathology in obese mice (P < 0.001) (92). The effect was 
explained mainly by the ability of vitamin D to reverse the obesity-induced increase in 
osteopontin and decrease in E-cadherin.  
Serum 25(OH)D concentrations may also affect circulating leptin levels (315), 
inflammatory markers (308), modulate glucose intolerance and insulin resistance (316;317), 
which are all factors contributing to increased risk of cancer in overweight and obese persons 
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(318). Additionally, low serum 1,25(OH)2D levels, common in this group of patients, were 
recently linked to excess midterm mortality in patients with coronary heart disease, 
hypertension, diabetes, heart and renal failure (128;308). Moreover, serum 25(OH)D and 
1,25(OH)2D seem to be independent predictors of all-cause and cardiovascular mortality (319-
321), and survival from some vitamin D-sensitive cancers (322).   
 
11. CONCLUSIONS 
The aim of this work was to investigate the impact of vitamin D predictors (UV exposure, 
BMI, vitamin D intake) on vitamin D status and cancer risk.  
The effect of UV exposure and vitamin D intake on serum 25(OH)D concentrations 
were evaluated in interventional studies. We have simulated a Norwegian summer by exposure 
to commercial, UV-emitting tanning units (two types) with ~2 % of UVB280-320nm. We have 
also compared the efficiency of high dose oral vitamin D supplementation with moderate 
exposures to these tanning devices with respect to achieving a given increase in serum 
25(OH)D concentrations. Thus, based on interventional studies we may conclude that:  
 
 Moderate UV exposures given over 5-7 weeks may raise serum 25(OH)D 
concentrations from typical winter values to typical summer values. 
 The recommended by Holick sun exposure (¼ MED (~0.5-0.8 SED) daily to ¼ body 
skin surface) is most probably too small to provide optimal vitamin D status (25(OH)D 
 75 nmol/L). 
 The increase in serum 25(OH)D concentrations is dependent on initial vitamin D status: 
persons with the lowest baseline 25(OH)D concentrations have the largest increase. 
However, persons with vitamin D deficiency (25(OH)D < 50 nmol/L) do usually not 
reach vitamin D sufficiency (25(OH)D  75 nmol/L) after the mentioned UV exposure. 
 An oral vitamin D intake of 2,000 IU is almost equal to a whole body sun exposure of 
~0.2 MED (0.5-0.8 SED) corresponding to 5-7 minutes midday on a midsummer, 
cloudless day in Oslo. 
The associations between body composition, BMI, and 1,25(OH)2D concentrations were 
analyzed in 1779 adults and 102 children with overweight or obesity. The following 
conclusions were drawn: 
 
 The prevalence of vitamin D deficiency and insufficiency is increasing with BMI. 
Around 60-70 % of obese adults (BMI > 30 kg/m2) and 50 % of overweight and obese 
children have serum 25(OH)D < 75 nmol/L.  
 In adults, the serum 25(OH)D concentration is the strongest predictor of serum 
1,25(OH)2D concentration. A decrease in 25(OH)D by 1 nmol/L is associated with 0.4 
pmol/L decrease in serum 1,25(OH)2D. 
 There is no correlation between serum 25(OH)D and 1,25(OH)2D concentrations in 
children and adolescents with excess body weight.  
 Serum 1,25(OH)2D concentrations decrease with increasing BMI and adiposity. Older 
persons (> 50 years) have lower 1,25(OH)2D concentrations than younger persons (< 
30 years).  
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 Serum 25(OH)D and 1,25(OH)2D concentrations vary during the year. In obese and 
overweight adults there is a late summer peak for both serum 25(OH)D and 
1,25(OH)2D concentrations.  
 
We have also estimated possible contribution of obesity- related decrease in serum 25(OH)D 
concentrations on cancer risk. According to our calculations:  
 
 At least 20 % of the total cancer risk attributable to high BMI may be explained by low 
vitamin D status. 
 The contribution of vitamin D status to obesity- related cancer risk is different for 
different cancer types.  
 A low vitamin D status may explain 40 % of obesity-related risk BCa, and 26 % and 75 
% of obesity-related CRC risk in men and women, respectively. 
 
 
12. FUTURE PERSPECTIVES  
Over 300 clinical trials have been initiated recently to investigate the association between 
vitamin D status and cancer risk and survival (277;296). However, most of them are not yet 
accomplished. The results of these and other clinical trials will hopefully clarify the 
relationship between serum levels of vitamin D metabolites and cancer development and 
prognosis. Phase II and Phase III RCT are needed to elucidate the potential role of vitamin D 
metabolites and analogues in anti-cancer treatment. We plan to continue our work in this field 
and to investigate vitamin D status in the Norwegian cancer population linking it to cancer risk 
and prognosis.  
New guidelines for vitamin D supplementation and sun exposure are required in order 
to improve vitamin D status, both on individual and population levels. The recommended 
vitamin D intake and sun exposure should be reconsidered and, according to the present work, 
increased significantly. We aim to continue our work in developing these recommendations.  
In light of recent research, the regulations about UVB content in commercially 
available tanning units should be changed. Further research is needed in order to estimate 
possible impact of sun bed use on CMM risk.  
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Abstract
Solar UV radiation and food are the two naturally available and major sources of vitamin 
D for humans. At northern latitudes sun exposure provides enough vitamin D only during 
the summer. During the winter vitamin D intake becomes the most important source of 
vitamin D. Indoor tanning units are good sources of vitamin D as well, but their use are 
being debated because of the skin cancer risk associated with large exposures. The aim of 
the present study was to compare the efficiency of oral vitamin D3 supplementation (2000 
IU/d for 30 days) and 10 sun bed exposures of total dose 23.8 SED (vitamin D weighted 
dose 319 mJ/cm2) to improve the vitamin D status. Healthy volunteers were randomized 
into two groups: Group 1 received vitamin D supplementation at first and then continued 
with 10 whole body exposures. Group 2 started with 10 exposures and than continued 
with vitamin D supplementation. The oral supplementation with vitamin D3 was slightly 
more beneficial than exposure to UVB and resulted in serum 25(OH)D increase by 27.5 
nmol/L (SEM ± 3.5 nmol/L; P<0.01) vs. 22.9 nmol/L (SEM ± 5.0 nmol/L; P<0.01) in the 
UVB group. At the end of the study the pooled serum 25(OH)D increase was 31.3 
nmol/L (SEM ± 3.8 nmol/L; P<0.001), and 61 % of the volunteers had serum 25(OH)D  
75 nmol/L. Thus, a daily whole body exposure to 0.5 SED may be enough to achieve and 
maintain serum 25(OH)D concentrations  75 nmol/L. This dose almost equals to 2000 
IU/d of oral vitamin D supplementation, and about 2 hours of sun exposure weekly to 1/3 
skin surface area at Oslo latitude around midday during the summer.  
 3
Introduction  
Solar UVB radiation is the main source of vitamin D for humans (1). About 80-90% of 
total vitamin D is produced in the skin (1). Exposure of the whole body to the sun for 1 
minimal erythema dose (MED) ( ~2.5-3.5 standard erythema dose (SED)) under optimal 
conditions may be equivalent to 10 000 -25 000 IU of oral vitamin D (2). However, 
vitamin D synthesis is a self-regulated process, and under prolonged sun exposure both 
previtamin D and vitamin D are degraded to tachysterol and other photoproducts (2). 
Thus, excessive sun exposure does not result in vitamin D intoxication as was once 
thought, but it may cause DNA damage and sunburn and, thus, increase the risk for skin 
cancer (3).   
The sun exposure time needed for optimal vitamin D synthesis vary greatly with time of 
day, season, latitude, altitude and weather conditions (4-6). At Oslo latitude, 590N, 
vitamin D is produced in the skin only during the summer months (April – October) with 
the maximum vitamin D synthesis around noon 11 a.m. - 1 p.m. (7). Between November 
and March practically no synthesis of vitamin D occurs due to lack of UVB in solar 
radiation. Therefore, vitamin D supplementation is recommended during the winter to 
maintain a good vitamin D status (8). The recommended daily dose of vitamin D in 
Norway is 300 - 400 IU (7.5 - 10
g) (9). This is, according to recent literature, hardly 
enough to keep serum 25(OH)D concentrations >50 nmol/L (10). Artificial sources of 
UVB may also be good sources of vitamin D during the winter, however little is known 
how given doses of UVB radiation correspond to given doses of vitamin D 
supplementation, with respect to efficiency to increase serum 25(OH)D (11;12). 
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In a previous study, we  found that 10 sun bed exposures (total dose of 8.5 MED) were 
enough to reach summer serum 25(OH)D concentrations (12). A vitamin D 
supplementation of 200 IU per day following the exposures was far too little to maintain 
the achieved serum 25(OH)D values (12).  The present study was designed to investigate 
if a vitamin D supplementation with 2000 IU daily (tolerable upper limit for vitamin D 
intake according to the European Commission (13)) is efficient to remain serum 
25(OH)D levels achieved after 10 sun bed exposures. We also aimed to investigate if the 
initial vitamin D status effects the efficiency of UVB irradiation to increase serum 
25(OH)D levels.  
Materials and methods 
Volunteers 
A total of 31 healthy volunteers (8 men and 23 women), aged between 23 and 61 years, 
were recruited in the study. All volunteers were living in Oslo (59°N). 
The participants were asked to fill out questionnaires with questions about age, 
weigh, height, skin type, sun exposure and indoor tanning habits. The questionnaires 
contained also questions about dietary vitamin D intake with food and/or supplements.  
The exclusion criteria were: the presence of severe disorders and medical conditions 
known to effect vitamin D status; pregnancy or plans to become pregnant; high-dose 
vitamin D supplementation, winter vacations to southern latitudes and indoor tanning for 
8 weeks before initiation of the study or plans for traveling to southern latitudes during 
the study.   
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The study was approved by the Regional Ethical Committee. Each participant 
gave written informed consent.  
UVB source  
The source of UV radiation was a commercially available and approved type 3 sun bed 
(2,15% UVB: 280-320 nm), equipped with Golden Sun RS 100 W and Beauty Sun S 25 
W spaghetti tubes (Wolff System, Basel, Switzerland). The emission spectra of the sun 
bed and the sun (Oslo, 22 July 2010, 12.00 AM) were measured with a AvaSpec ULS 
fiber optic spectrometer using AvaSoft 7.3.1 (Avantes BV, NL-6961 RB Eerbeek, 
Netherlands) (Figure 1 A). Efficiency spectra of vitamin D formation were calculated 
based on action spectra of previtamin D3 synthesis in the human skin by Holick et al. 
(Figure 1 B) (14). CIE-weighted UV doses are presented as Standard Erythema Dose 
(SED; 1 SED = 100 J/m2). The SED is equivalent to about 0.5 MED for the most 
sensitive type 1 skin (1 MED = 200 J/m2) (4).  
Design and protocol of the study 
The study was carried out during the winter months (January - March) in order to avoid 
any 25(OH)D contribution from solar radiation. All volunteers were recruited between 
December 2007 and February 2008. The study extended over 9 weeks. 
The participants were randomly assigned into two groups (Figure 2). Group 1 (n0=15) 
received 2000 IU (50
g) of vitamin D3 (J.R. Carlson Laboratories, Inc., IL 60004-1985) 
daily for 30 days, then continued with 10 whole body sun bed exposures (1.- 7 min (1.3 
SED); 2-3.- 10 min (1.9 SED); 4-5.-13 min (2.4 SED); 6-10.- 15 min (2.8 SED)) twice a 
week with a total dose of 23.8 SED (vitamin D weighted: 134 J/m2 per 1 SED). Group 2 
(n0=16) started with 10 sun bed exposures following the same exposure schedule as 
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Group 1 with a total dose of 24 SED, then continued with 2000 IU (50
g) of vitamin D3 
daily for 30 days. Individual MED were determined at the baseline to avoid any sun 
burns. Four skin areas (2x2cm) on the anterior forearm were exposed to different doses of 
UV (10 – 15 – 20 –25 min). The skin reaction was evaluated 24h after exposure.  
Blood sampling and methods of analyses 
Blood samples were taken at the baseline, after first intervention (vitamin D 
supplementation (Group 1), after 10 sun bed exposures (Group 2)) and at the end of the 
study. Serum was separated from the blood cells by centrifugation and then frozen to 
20 °C. All serum samples in batch were analyzed in Haukeland University Hospital, 
Bergen, Norway. The 25(OH)D assay was performed by liquid chromatography-mass 
spectrometry method (LC MSD SL; Agilent Technology, CA).The assay was performed 
according to a modified version of the method described elsewhere (11). The mean 
recovery of 25(OH)D was 77.2% (SD 3.9%) and the interassay variation was 4.9%, with 
a detection limit < 4 nmol/l. 
Statistical analysis
The data were analyzed using Sigma Plot 10.0 for Windows. The values of the variables 
were presented as means ± SEM.  The criterion for statistical significance was defined as 
P < 0.05.   
Results
The spectral characteristics of the sun bed used in the study and that of the midday, 
midsummer sun are shown on Figure 1A. According to our calculations, based on 
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efficiency spectra of previtamin D3 formation of these two UVB sources, the sun bed was 
about 25-30 % less efficient in producing previtamin D3 than the sun.   
Of the 31 volunteers recruited in the study, 25 subjects completed the second 
phase of intervention (Figure 2). Four persons withdrew from the study during the 
supplementation part and two persons during the sun bed treatment for reasons unrelated 
to the interventions. No side-effects were observed.  
The baseline characteristics of the two groups are shown in Table 1. There was no 
significant difference in mean age, BMI, vitamin D intake or serum 25(OH)D 
concentrations at baseline between the groups, although volunteers in Group 1 had 8.2 
nmol/L higher serum 25(OH)D than those in Group 2. The mean serum 25(OH)D 
concentration at baseline for the whole group was 50.2 ± 3.61 nmol/L. Only 3 persons 
(10%) had serum 25(OH)D > 75nmol/L. Serum 25(OH)D concentrations < 50nmol/L 
were observed in 15 volunteers (50%).  
After the first phase of intervention serum 25(OH)D concentrations increased 
significantly in both groups (P<0.01) (Figure 3).  Serum  25(OH)D concentrations 
increased by  27.5 ± 3.48 nmol/L in Group 1 after vitamin D3 supplementation and by 
22.9 ± 3.48 nmol/L in Group 2 after 10 sun bed exposures (P = 0.49) (Figure 4).  The 
second phase of intervention resulted in a slight and non-significant further increase in 
serum 25(OH)D (Figure 3, 4). This is to be expected since serum 25(OH)D 
concentrations usually plateau after 4-6 weeks of intervention (15;16). The total increase 
was similar in both groups (Figure 4, Table 1). Although the serum 25(OH)D 
concentrations at the end of the study were highest in Group 1, the relative increase was 
similar in both groups (Table 1).  
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The absolute increase was also similar in participants with baseline serum 
25(OH)D concentrations < 50 nmol/L and > 50 nmol/L (Figure 5). However, the 
achieved serum 25(OH)D concentrations were highest in the group with high baseline 
25(OH)D (Figure 5). 
 The increase in serum 25(OH)D in Group 2 after the first phase of intervention 
(10 sun bed exposures) was to some extent greater in persons with low BMI compared 
than in persons with high BMI, but not significantly (data not shown). No correlation 
between absolute increase in serum 25(OH)D and BMI was observed after vitamin D 
supplementation. This might be due to rather small differences in BMI between 
volunteers. The majority of participants had BMI within the normal range (18-24.9 
kg/m2), or were overweight (BMI 25-29.9 kg/m2). Only one volunteer had BMI > 30 
kg/m2. 
 
Discussion  
Although there is no consistent definition of vitamin D deficiency, sufficient vitamin D 
status is usually defined as serum 25(OH)D concentrations 75 nmol/L (17;18). This 
cutoff point is based on evaluations of the biological effect serum 25(OH)D levels on  
serum concentrations of PTH levels and clinical data that supports a protective effect of 
vitamin D against a number of diseases (18;19). 
 Serum 25(OH)D concentrations vary with season with the lowest values observed 
during the winter and early spring (20). Our study shows that only 3 adults (10%) among 
31 volunteers had sufficient vitamin D status in the middle of the winter (January 2008). 
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This is in agreement with other investigations that reported the prevalence of vitamin D 
sufficiency to be  as low as 10-20% during the winter months (19;21).  
 In Norway and other northern countries the highest serum 25(OH)D 
concentrations were observed in July-September with the mean values above 60-80 
nmol/L (21). The late summer 25(OH)D values predict the vitamin D status during the 
following winter monthes. It has been calculated by Webb at al. that a circulating 
25(OH)D levels 80nmol/L at the end of the summer are required in order to maintain 
25(OH)D values 50 nmol/L during the following winter (22). However, several recent 
studies found that current sun exposure habits do not provide for the required vitamin D 
status for most people (21-23). According to Christensen et al. only 44% of persons from 
Western Norway have serum 25(OH)D >75 nmol/L at the end of the summer (21).  The 
results of the recent study performed in Greater Manchester, UK, indicate that  exposure 
to 0.5 SED daily between 11 a.m. and 1 p.m. in real life conditions (typical summer 
clothing) is not enough to reach the level of vitamin D sufficiency at the end of the 
summer (22). Based on the results of our study, we may conclude that a whole body 
exposure to at least 0.5 SED (5-6 minutes) may be needed to reach and maintain an 
optimal vitamin D status. This is in agreement with the study conducted in Copenhagen, 
Denmark, that suggested the serum 25(OH)D concentrations 80 nmol/L in September 
may be achieved by daily sun exposure to 1.4 SED in real life conditions (24).  
In order to maintain 25(OH)D  80nmol/L during the winter, vitamin D 
supplementation is recommended. Holick et al. reported that 1000 IU/d of vitamin D in 
the winter for 11 weeks was ineffective in raising the blood levels  75 nmol/L (16). 
According to the recent study by Cashman et al. 920-1640 IU may be required to keep 
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late summer 25(OH)D concentrations throughout the year if supplementation is started in 
the autumn (10). Thus, higher doses of vitamin D supplementation (2000-3000 IU) may 
be considered necessary to reach those values if supplementation is started later in the 
winter when initial levels are low (25). The response of serum 25(OH)D to each 100 IU 
vitamin D ingested vary from 2.5 nmol/L in persons with low initial levels to 1.5 nmol/L 
or less for those with high serum 25(OH)D at baseline (15;16).  
Alternatively, artificial UV sources can be used to improve vitamin D status 
during the winter (11;26).  However, little is known about any interaction between 
vitamin D supplementation and UV exposure necessary to improve and maintain 
25(OH)D levels > 75 nmol/L.  
According to Holick’s rule: “Exposure of ¼ body skin surface to the sun for ¼ 
MED (~0.5-0.8 SED) at 42°N (Boston) in March would be equally efficient to 1000 IU 
(25
g) of vitamin D intake” (14). The exposure required for vitamin D production equal 
to 1000 IU oral intake is also called a standard vitamin D dose (SDD), and for skin type 
II person corresponding to a vitamin D weighted dose of 106-110 J/m2 or, based on 
Holick’s rule, to ~7 minutes sun exposure to ¼ of body surface at Oslo latitude (4;5). 
According to calculations performed by Webb and Engelsen for SDD at 62.5°N latitude 
(6), a person with skin type II to III would need to spend ~9-11 minutes in the sun at 
around 12:00 a.m. in order to reach SDD. 
Our results suggest that not even a dose of  91 J/m2 (vitamin D weighted) of 
whole body exposure is equivalent to 1000 IU vitamin D intake. Similar conclusions 
were drawn by Thieden et al., who has conducted a study on healthy volunteers with sun 
bed exposure in the daily dose of ~140 J/m2 (vitamin D weighted) for 18 days (26). This 
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dose was exactly enough to increase serum 25(OH)D concentrations up to 75.3 nmol/L 
(26).  Rhodes et al.  also concluded that the recommended sun exposure can produce 
25(OH)D concentrations  50nmol/L, but not the proposed sufficient 25(OH)D levels 
(27).  
The effectiveness of UVB exposure to increase serum 25(OH)D concentrations 
may also be dependent on initial vitamin D status. As it has been shown by us and other 
investigators, low initial 25(OH)D concentrations were associated with large absolute and 
relative increases in serum 25(OH)D, irrespective of UVB dose (11;28;29). In the present 
study we have also observed this trend (Figure 5). However, adults who were vitamin D 
deficient did reach serum 25(OH)D levels  75 nmol/L after intervention.  
Several studies have also suggested that genetic factors may explain the 
interindividual variation in serum 25(OH)D concentrations (30;31). In fact, genetic 
variations at specific loci may substantially affect vitamin D status. Recently, three  such 
loci were identified. These are genes involved in cholesterol synthesis from 7-DHC, 
hydroxylation of vitamin D to 25(OH)D, and vitamin D transport (30). The combination 
of impaired alleles at all three loci more than doubles the risk of vitamin D insufficiency 
(30). Moreover, genetic predisposition may explain about 50% of variability in serum 
25(OH)D during the summer (31). This can at least in part explain the discrepancy 
between calculated and actual UV dose required for optimal vitamin D production.  
One should also remember that in the most models used for calculations of SDD a 
flat horizontal surface model (pancake model) was used (4-6). This model does not take 
into account the geometry of the human body and the surface of the skin that is not 
directly exposed to the sun. Thus, the time required to reach SDD may be longer than 
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predicted by the calculations. In the case of calculations for whole body exposure this 
time should be doubled, since only half of the body can be exposed to the sun at any time 
(29).    
Besides season and time of the day, SDD may also vary largely with real 
atmospheric conditions, orientation of the skin surface and of sun screams use (4-6). 
From this point of view, use of indoor tanning units could be more controllable and 
beneficial than real sun exposure since whole body area can be exposed to UVB radiation 
of equal intensity. Whole body exposure will also reduce the time of sun or sun bed 
exposure required for an optimal vitamin D synthesis. However, a growing body of 
evidence suggests that the modern sun beds may increase the risk of skin cancer (32;33). 
This might be due to strong UVA radiation emitted by many sun beds, in some of them 
being 3-10 times stronger compared to the sun. At the same time, careful sun exposure 
does not seem to increase the skin cancer risk and still can be recommended to improve 
vitamin D status during the summer.  
However, vitamin D supplementation may be the safest way for improving the vitamin D 
status. Based on the results of our study, oral vitamin D supplementation with 2000 IU is 
equally or more effective to increase serum 25(OH)D concentrations than 10 sun bed 
exposures. A daily supplementation with 2000 IU results in an increase of serum 
25(OH)D by 25-30 nmol/L, which is in most cases enough to achieve and maintain 
vitamin D sufficiency. Thus, the recommended daily dose (400 IU) should be 
reconsidered and increased significantly. No vitamin D toxicity has been observed for 
vitamin D supplementation <10,000 IU (34).  
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Table 1
Characteristics of study population.  
 
Group 1 Group 2 P value 
Vitamin D intake*, µg/day 6.7 ± 1.4 6.6 ± 1.0 0.98 
BMI, kg/m2 23.3 ± 0.8 24.5 ± 1.0 0.33 
Age, years  36.3 ± 2.9 39.3 ± 3.3 0.50 
Skin type** I; II; III; IV 2;8;4;1 2;10;3;1 0.78 
   
Initial 25(OH)D levels, nmol/L (SEM) 52.5 ± 4.0 44.3 ± 4.5 0.19 
   25(OH)D after FF#, nmol/L (SEM) 80.9 ± 4.1 67.2 ± 4.9 0.05 
   25(OH)D after SF¤, nmol/L (SEM) 84.8 ± 5.1 76.3 ± 6.2 0.32 
Absolute 25(OH)D increase, nmol/L (SEM) 31.2 ± 5.0 31.3 ± 5.6 0.99 
Relative 25(OH)D increase, % 66.5 ± 13.9 89.9 ± 24.3 0.44 
*Self-reported vitamin D intake calculated based on food frequency questionnaire 
**Self-reported skin type according to Fitzpatrick classification  
#Fisrt phase, ¤Second phase 
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Figure 1
 
Spectral characteristics of the sun bed used in the study and of the sun at noon midsummer in 
Oslo (22 July 2010). Action (A) and efficiency (B) spectra of vitamin D3 formation in the 
skin.  
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Figure 2
Diagram showing flow of subjects through the study and study design. 
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Figure 3
Serum concentrations of serum 25(OH)D in two groups at baseline, after the first and the 
second phase of intervention. Data are means ± SEM. There was a significant increase in 
serum 25(OH)D during the first phase of intervention.  
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Figure 4 
 
Absolute serum 25(OH)D increase after first and second intervention phases. Data are 
means ± SEM. 
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Figure 5 
 
Serum 25(OH)D increase after two intervention phases in vitamin D deficient and non-
deficient persons. Data are means ± SEM. Means with superscripts without a common 
letter differ, P<0.05. 
 
 
 
 
 
 
